BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Biotech Catalyst Calendar//2027//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:2027 Biotech Catalyst Calendar
X-WR-CALDESC:Key 2027 biotech catalysts with confirmed calendar dates. Full calendar: https://risdiplam.github.io/biotech-catalyst-calendar/
BEGIN:VEVENT
UID:v16-0021@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270228
SUMMARY:APMD — AD109 (aroxybutynin + atomoxetine) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Obstructive sleep apnea\nThe FDA's decision date on AD109 (aroxybutynin + atomoxetine) for Obstructive sleep apnea falls on 2027-02-28 — the agency's yes-or-no moment for Apnimed\, Inc.'s application.\nNote: FDA accepted NDA for AD109 (aroxybutynin + atomoxetine) in obstructive sleep apnea (Phase 3 SynAIRgy and LunAIRo)\; PDUFA date February 28\, 2027. Apnimed completed an upsized IPO and began trading on the Nasdaq Global Select Market as APMD on 2026-07-31.\nDate quality: hard (2027-02-28)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0021\nSource: https://www.prnewswire.com/news-releases/apnimed-announces-fda-acceptance-of-new-drug-application-for-ad109-an-investigational-oral-pill-to-treat-adults-with-obstructive-sleep-apnea-osa-302825008.html
END:VEVENT
BEGIN:VEVENT
UID:v16-0023@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270501
SUMMARY:AXSM — AXS-12 (reboxetine) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: cataplexy in narcolepsy\nNote: FDA accepted NDA\; PDUFA May 1\, 2027\; no AdCom planned. [Source verified 2026-09-20: 'The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1\, 2027. The FDA also indicated that it does not currently plan to hold an advisory committee meeting to discuss the application.' (July]\nDate quality: hard (2027-05-01)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0023\nSource: https://www.globenewswire.com/news-release/2026/07/15/3327580/33090/en/axsome-therapeutics-announces-fda-acceptance-of-new-drug-application-for-axs-12-for-the-treatment-of-cataplexy-in-narcolepsy.html
END:VEVENT
BEGIN:VEVENT
UID:v16-0046@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270508
SUMMARY:BBIO — encaleret PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: autosomal dominant hypocalcemia type 1 (ADH1)\nNote: FDA accepted NDA\; PDUFA May 8\, 2027\; no AdCom planned\; no approved or advanced competitor in ADH1.\nDate quality: hard (2027-05-08)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0046\nSource: https://investor.bridgebio.com/news/news-details/2026/BridgeBio-Announces-FDA-Acceptance-of-NDA-for-Encaleret-for-ADH1/default.aspx
END:VEVENT
BEGIN:VEVENT
UID:v16-0062@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270513
SUMMARY:BMY — mezigdomide PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: relapsed/refractory multiple myeloma\nNote: FDA accepted NDA for mezigdomide (MeziKd: oral mezigdomide + carfilzomib + dexamethasone) in relapsed/refractory multiple myeloma\, based on Phase 3 SUCCESSOR-2 (NCT05552976\; PFS 18.0 vs 8.3 months\, HR 0.48\, p<0.0001). BMS PR 2026-07-13: 'The FDA has granted a Prescription Drug User Fee Act (PDUFA) date of May 13\, 2027 for this indication.' GAP: acceptance letter text not viewed\; acceptance confirm\nDate quality: hard (2027-05-13)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0062\nSource: https://www.businesswire.com/news/home/20260713597234/en/U.S.-Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-New-Drug-Application-for-Mezigdomide-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma
END:VEVENT
BEGIN:VEVENT
UID:v16-0073@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270121
SUMMARY:DYN — zeleciment rostudirsen (z-rostudirsen\, DYNE-251) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Duchenne muscular dystrophy amenable to exon 51 skipping\nPhase 3 data for z-rostudirsen (DYNE-251) in Duchenne muscular dystrophy amenable to exon 51 skipping is expected on 2027-01-21 — the pivotal readout that determines whether Dyne Therapeutics\, Inc. can file for approval.\nNote: FDA accepted BLA and granted Priority Review\; exact PDUFA date disclosed in company PR.\nDate quality: hard (2027-01-21)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0073\nSource: https://www.globenewswire.com/news-release/2026/07/20/3329635/0/en/Dyne-Therapeutics-Announces-U-S-FDA-Acceptance-of-Biologics-License-Application-BLA-for-Z-Rostudirsen-in-Exon-51-Duchenne-Muscular-Dystrophy-DMD.html
END:VEVENT
BEGIN:VEVENT
UID:v16-0076@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270629
SUMMARY:COGT — bezuclastinib PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: advanced systemic mastocytosis (AdvSM)\nThe FDA's decision date on bezuclastinib for advanced systemic mastocytosis (AdvSM) falls on 2027-06-29 — the agency's yes-or-no moment for Cogent Biosciences\, Inc.'s application.\nNote: FDA accepted NDA and set PDUFA target action date 2027-06-29\; no AdCom planned at this time. NonAdvSM (2026-12-30) and GIST (2026-11-30) PDUFAs fall in 2026. [Source verified 2026-09-20: FDA has accepted its New Drug Application (NDA) for bezuclastinib in patients with Advanced Systemic Mastocytosis (AdvSM) and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 29\, 2027. \nDate quality: hard (2027-06-29)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0076\nSource: https://www.globenewswire.com/news-release/2026/09/15/3361988/0/en/cogent-biosciences-announces-fda-acceptance-of-new-drug-application-nda-for-bezuclastinib-in-patients-with-advanced-systemic-mastocytosis-advsm.html
END:VEVENT
BEGIN:VEVENT
UID:v16-0080@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270227
SUMMARY:CGEM — zipalertinib PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations after platinum-based chemotherapy\nThe FDA's decision date on zipalertinib for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations after platinum-based chemotherapy falls on 2027-02-27 — the agency's yes-or-no moment for Cullinan Therapeutics\, Inc.'s application.\nNote: FDA accepted NDA (post-platinum\, with or without prior amivantamab) with PDUFA 2027-02-27 per Cullinan/Taiho\; REZILIENT3 first-line Ph3 read out 2026\, not a 2027 event.\nDate quality: hard (2027-02-27)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0080\nSource: https://www.taihooncology.com/us/news/us-food-and-drug-administration-accepts-new-drug-application-for-zipalertinib-for-the-treatment-of-locally-advanced-or-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations/
END:VEVENT
BEGIN:VEVENT
UID:v16-0086@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270303
SUMMARY:EXEL — zanzalintinib (XL092) + atezolizumab (Tecentriq) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: previously treated metastatic colorectal cancer\nNote: FDA extended the original 2026-12-03 target action date to 2027-03-03 after updated safety and efficacy data submitted in response to an FDA information request were classified as a major amendment. Disclosed by the company via Form 8-K (Item 8.01) filed 2026-09-11\; no standalone company PR exists — sourced via Reuters' direct quote of the filing.\nDate quality: hard (2027-03-03)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0086\nSource: https://www.sec.gov/cgi-bin/browse-edgar?CIK=EXEL&owner=exclude&action=getcompany&Find=Search
END:VEVENT
BEGIN:VEVENT
UID:v16-0094@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270202
SUMMARY:GILD — Yeztugo (lenacapavir\, oral once-weekly) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: HIV pre-exposure prophylaxis\nNote: FDA accepted the NDA for the once-weekly oral formulation\, potentially the first long-acting pill for HIV prevention\; standard-review action date 2027-02-02.\nDate quality: hard (2027-02-02)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0094\nSource: https://www.gilead.com/news/news-details/2026/u-s--fda-accepts-gileads-application-for-investigational-once-weekly-oral-yeztugo-potentially-the-first-long-acting-pill-for-hiv-prevention
END:VEVENT
BEGIN:VEVENT
UID:v16-0101@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270401
SUMMARY:HRMY — pitolisant GR (gastro-resistant tablets) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: narcolepsy\nNote: Pitolisant GR = gastro-resistant tablets (not granules)\, pediatric narcolepsy formulation\; NDA accepted by FDA July 2026\; target PDUFA date 2027-04-01 per Q2 2026 company update.\nDate quality: hard (2027-04-01)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0101\nSource: https://www.globenewswire.com/news-release/2026/08/04/3338190/0/en/Harmony-Biosciences-Announces-Record-Q2-2026-Revenue-and-Shares-Initial-Clinical-Data-for-Its-Orexin-2-Agonist-BP-205-Reinforcing-Potential-Best-in-Class-Profile.html
END:VEVENT
BEGIN:VEVENT
UID:v16-0108@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270428
SUMMARY:IMNM — varegacestat (AL102) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: desmoid tumors\nThe FDA's decision date on varegacestat (AL102) for desmoid tumors falls on 2027-04-28 — the agency's yes-or-no moment for Immunome\, Inc.'s application.\nNote: FDA accepted the NDA for the gamma-secretase inhibitor in adults with desmoid tumors\; action date 2027-04-28.\nDate quality: hard (2027-04-28)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0108\nSource: https://investors.immunome.com/immunome-announces-u-s-fda-acceptance-of-new-drug-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/
END:VEVENT
BEGIN:VEVENT
UID:v16-0116@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270414
SUMMARY:INBX — ozekibart (INBRX-109) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: unresectable or metastatic conventional chondrosarcoma\nThe FDA's decision date on ozekibart (INBRX-109) for unresectable or metastatic conventional chondrosarcoma falls on 2027-04-14 — the agency's yes-or-no moment for Inhibrx Biosciences\, Inc.'s application.\nNote: FDA accepted BLA (no filing review issues)\; PDUFA goal April 14\, 2027. Would be first FDA-approved therapy for chondrosarcoma.\nDate quality: hard (2027-04-14)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0116\nSource: https://www.prnewswire.com/news-releases/inhibrx-announces-us-fda-acceptance-of-bla-for-ozekibart-in-patients-with-conventional-chondrosarcoma-302800101.html
END:VEVENT
BEGIN:VEVENT
UID:v16-0127@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270128
SUMMARY:INSM — ARIKAYCE (amikacin liposome inhalation suspension) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: MAC lung disease (newly diagnosed) — ENCORE (Phase 3b)\nNote: FDA accepted the sNDA for ARIKAYCE (amikacin liposome inhalation suspension) in MAC lung disease and granted Priority Review\; PDUFA target action date January 28\, 2027 (company PR 2026-09-21). Expands to newly diagnosed MAC and converts the 2018 accelerated approval.\nDate quality: hard (2027-01-28)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0127\nSource: https://www.prnewswire.com/news-releases/fda-grants-priority-review-to-insmeds-snda-for-arikayce-amikacin-liposome-inhalation-suspension-for-treatment-of-mac-lung-disease-with-pdufa-target-action-date-set-for-january-28-2027-302884017.html
END:VEVENT
BEGIN:VEVENT
UID:v16-0185@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270310
SUMMARY:NTLA — lonvoguran ziclumeran (lonvo-z) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: hereditary angioedema\nThe FDA's decision date on lonvoguran ziclumeran (lonvo-z) for hereditary angioedema falls on 2027-03-10 — the agency's yes-or-no moment for Intellia Therapeutics\, Inc.'s application.\nNote: BLA accepted with priority review\; PDUFA 2027-03-10\; FDA currently does not plan an AdCom. [Source verified 2026-09-20: Official Intellia GlobeNewswire release (opened and confirmed 2026-09-20): "today announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lonvo-z and granted the BLA]\nDate quality: hard (2027-03-10)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0185\nSource: https://www.globenewswire.com/news-release/2026/09/08/3357599/0/en/intellia-therapeutics-announces-fda-acceptance-of-biologics-license-application-with-priority-review-for-lonvoguran-ziclumeran-lonvo-z-for-hereditary-angioedema-hae.html
END:VEVENT
BEGIN:VEVENT
UID:v16-0188@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270423
SUMMARY:PHVS — Deucrictibant immediate-release PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: On-demand treatment of hereditary angioedema attacks (age 12+)\nThe FDA's decision date on deucrictibant immediate-release for on-demand treatment of hereditary angioedema attacks (age 12+) falls on 2027-04-23 — the agency's yes-or-no moment for Pharvaris N.V.'s application.\nNote: FDA accepted the NDA for deucrictibant IR for on-demand HAE attacks\; PDUFA target action date is April 23\, 2027 per company announcement.\nDate quality: hard (2027-04-23)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0188\nSource: https://www.biospace.com/press-releases/pharvaris-announces-fda-acceptance-of-new-drug-application-for-deucrictibant-ir-for-on-demand-treatment-of-hereditary-angioedema-attacks
END:VEVENT
BEGIN:VEVENT
UID:v16-0191@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270424
SUMMARY:ORGO — ReNu PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Management of symptomatic knee osteoarthritis pain\nThe FDA's decision date on ReNu for Management of symptomatic knee osteoarthritis pain falls on 2027-04-24 — the agency's yes-or-no moment for Organogenesis Holdings Inc.'s application.\nNote: FDA accepted the BLA for ReNu for symptomatic knee OA\; PDUFA target action date is April 24\, 2027 per company announcement.\nDate quality: hard (2027-04-24)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0191\nSource: https://www.biospace.com/press-releases/organogenesis-announces-fda-acceptance-of-biologics-license-application-for-renu-for-the-management-of-symptomatic-knee-osteoarthritis
END:VEVENT
BEGIN:VEVENT
UID:v16-0192@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270129
SUMMARY:PRAX — Ulixacaltamide HCl PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Essential tremor in adults\nThe FDA's decision date on Ulixacaltamide HCl for Essential tremor in adults falls on 2027-01-29 — the agency's yes-or-no moment for Praxis Precision Medicines\, Inc.'s application.\nNote: FDA accepted the NDA for ulixacaltamide in essential tremor with PDUFA date January 29\, 2027\; FDA indicated it does not currently plan an Advisory Committee meeting.\nDate quality: hard (2027-01-29)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0192\nSource: https://www.globenewswire.com/news-release/2026/04/14/3273225/0/en/Praxis-Precision-Medicines-Announces-FDA-Acceptance-of-New-Drug-Application-for-Ulixacaltamide-HCl-in-Patients-with-Essential-Tremor.html
END:VEVENT
BEGIN:VEVENT
UID:v16-0200@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270110
SUMMARY:RHHBY — satralizumab (Enspryng) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)\nNote: FDA granted Priority Review of the sBLA for Enspryng in MOGAD with a target action date of January 10\, 2027. Source disagreement documented: CheckRare lists January 20\, 2027\; Roche's own disclosure (primary source) states January 10\, 2027 and is kept.\nDate quality: hard (2027-01-10)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0200\nSource: https://www.businesswire.com/news/home/20260909654496/en/U.S.-FDA-Grants-Priority-Review-for-Genentechs-Enspryng-for-MOGAD-an-Autoimmune-Disease-With-No-Approved-Treatments
END:VEVENT
BEGIN:VEVENT
UID:v16-0202@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270228
SUMMARY:SRPT — casimersen (AMONDYS 45) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Duchenne muscular dystrophy amenable to exon 45 skipping\nNote: FDA accepted the sNDA seeking traditional approval of AMONDYS 45 and assigned a PDUFA date of February 28\, 2027.\nDate quality: hard (2027-02-28)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0202\nSource: https://www.businesswire.com/news/home/20260630779541/en/Sarepta-Announces-FDA-Acceptance-of-sNDAs-for-AMONDYS-45-and-VYONDYS-53
END:VEVENT
BEGIN:VEVENT
UID:v16-0203@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270228
SUMMARY:SRPT — golodirsen (VYONDYS 53) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Duchenne muscular dystrophy amenable to exon 53 skipping\nNote: FDA accepted the sNDA seeking traditional approval of VYONDYS 53 and assigned a PDUFA date of February 28\, 2027.\nDate quality: hard (2027-02-28)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0203\nSource: https://www.businesswire.com/news/home/20260630779541/en/Sarepta-Announces-FDA-Acceptance-of-sNDAs-for-AMONDYS-45-and-VYONDYS-53
END:VEVENT
BEGIN:VEVENT
UID:v16-0216@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270624
SUMMARY:UTHR — oral ralinepag PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: pulmonary arterial hypertension (PAH)\nNote: FDA accepted the ralinepag NDA (announced Aug 24\, 2026) and set PDUFA target action date 2027-06-24 (company PR).\nDate quality: hard (2027-06-24)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0216\nSource: https://ir.unither.com/press-releases/2026/08-24-2026-120021913
END:VEVENT
BEGIN:VEVENT
UID:v16-0233@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270121
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: ASCO Gastrointestinal Cancers Symposium\, January 21–23\, 2027\, San Francisco\, CA. ASCO multidisciplinary GI oncology symposium.\nDate quality: hard (2027-01-21)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0233\nSource: https://www.asco.org/gi/dates-know
END:VEVENT
BEGIN:VEVENT
UID:v16-0234@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270210
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: International Stroke Conference 2027\, February 10–12\, 2027\, George R. Brown Convention Center\, Houston\, Texas. AHA annual stroke science meeting (pre-cons February 9).\nDate quality: hard (2027-02-10)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0234\nSource: https://professional.heart.org/en/meetings
END:VEVENT
BEGIN:VEVENT
UID:v16-0235@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270211
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: February 11-13\, 2027 (ASCO save-the-date page\, organizer-owned). Venue: San Francisco\, CA per 2027 edition listings (third party\; ASCO page excerpt does not name the city)\; prior editions held at Moscone Center\, San Francisco.\nDate quality: hard (2027-02-11)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0235\nSource: https://www.asco.org/gu
END:VEVENT
BEGIN:VEVENT
UID:v16-0236@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270228
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: AACR Immuno-Oncology 2027\, February 28–March 3\, 2027\, JW Marriott Los Angeles L.A. Live\, Los Angeles\, California. Immuno-oncology discovery-to-clinical conference.\nDate quality: hard (2027-02-28)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0236\nSource: https://www.aacr.org/meeting/aacr-io-2027/
END:VEVENT
BEGIN:VEVENT
UID:v16-0237@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270402
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: AACR Annual Meeting 2027\, April 2–7\, 2027\, Orange County Convention Center\, Orlando\, Florida.\nDate quality: hard (2027-04-02)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0237\nSource: https://www.aacr.org/meeting/aacr-annual-meeting-2027/
END:VEVENT
BEGIN:VEVENT
UID:v16-0238@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270410
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: ACC Annual Scientific Session 2027 (ACC.27-WCC)\, April 10–12\, 2027\, Houston\, Texas. ACC/World Heart Federation flagship cardiology meeting (pre-conference April 9).\nDate quality: hard (2027-04-10)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0238\nSource: https://accscientificsession.acc.org/Registration-and-Hotels
END:VEVENT
BEGIN:VEVENT
UID:v16-0239@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270604
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: ASCO Annual Meeting 2027\, June 4–8\, 2027\, McCormick Place\, Chicago\, IL. (Organizer dates-know page verified 2026-09-23.)\nDate quality: hard (2027-06-04)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0239\nSource: https://www.asco.org/annual-meeting/dates-know?intcmp=nw_ascoorg_am_ascovoices_site_amlandingpage_all__glob_092925__qklnk__aware_text_
END:VEVENT
BEGIN:VEVENT
UID:v16-0240@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270605
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: ENDO 2027\, June 5–7\, 2027\, Toronto\, Ontario\, Canada. Endocrine Society signature annual meeting.\nDate quality: hard (2027-06-05)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0240\nSource: https://endocrine.org/meetings-and-events/endo-future-meetings
END:VEVENT
BEGIN:VEVENT
UID:v16-0241@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270610
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: EHA2027 Congress\, June 10–13\, 2027\, Barcelona\, Spain. European Hematology Association annual congress.\nDate quality: hard (2027-06-10)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0241\nSource: https://ehaweb.org/connect-network/eha2027-congress
END:VEVENT
BEGIN:VEVENT
UID:v16-0242@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270718
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Alzheimer’s Association International Conference 2027\, July 18–21\, 2027\, Chicago\, United States\, and online. World’s largest dementia science meeting.\nDate quality: hard (2027-07-18)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0242\nSource: https://www.alz.org/research/for_researchers/scientific-conferences?lang=en-US&form=FUNSETYDEFK&form=FUNYWTPCJBN
END:VEVENT
BEGIN:VEVENT
UID:v16-0243@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270719
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: AHA BCVS Scientific Sessions 2027\, July 19–22\, 2027\, Westin Boston Seaport District\, Boston\, Massachusetts. Basic cardiovascular sciences sessions.\nDate quality: hard (2027-07-19)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0243\nSource: https://professional.heart.org/en/meetings
END:VEVENT
BEGIN:VEVENT
UID:v16-0244@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270722
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: AHA Vascular Discovery: From Genes to Medicine Scientific Sessions 2027\, July 22–25\, 2027\, Westin Boston Seaport District\, Boston\, Massachusetts. Vascular biology research meeting.\nDate quality: hard (2027-07-22)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0244\nSource: https://professional.heart.org/en/meetings
END:VEVENT
BEGIN:VEVENT
UID:v16-0245@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270827
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: ESC Congress 2027\, August 27–30\, 2027\, Milan\, Italy. World’s foremost cardiology meeting. (Dates + city per ESC\; specific venue not printed.)\nDate quality: hard (2027-08-27)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0245\nSource: https://www.escardio.org/events/congresses/esc-congress/
END:VEVENT
BEGIN:VEVENT
UID:v16-0246@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270911
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: 2027 World Conference on Lung Cancer\, September 11-14\, 2027\, Denver\, Colorado. IASLC annual lung cancer meeting. (Organizer press release 2025-12-16.) [2026-09-27 link audit] Replaced access-denied IASLC search URL with the official IASLC press release\; confirms Sep 11-14\, 2027\, Denver.\nDate quality: hard (2027-09-11)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0246\nSource: https://www.iaslc.org/iaslc-news/press-release/global-lung-cancer-experts-selected-lead-iaslcs-2027-world-conference
END:VEVENT
BEGIN:VEVENT
UID:v16-0248@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270921
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: 63rd EASD Annual Meeting\, September 21–24\, 2027\, Budapest\, Hungary. European diabetes research congress.\nDate quality: hard (2027-09-21)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0248\nSource: https://www.easd.org/annual-meeting/
END:VEVENT
BEGIN:VEVENT
UID:v16-0249@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270928
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: 32nd World Muscle Society (WMS) Congress\, September 28 - October 2\, 2027\, Helsinki\, Finland. Source: WMS official journal (Neuromuscular Disorders) general information page with Future WMS Meeting Dates (organizer-affiliated\, verified 2026-09-18\; direct curl probes get bot-blocked 403). Source upgraded 2026-09-18: WMS official events page directly exposes Sep 28-Oct 2 2027 Helsinki dates.\nDate quality: hard (2027-09-28)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0249\nSource: https://www.worldmusclesociety.org/m/events
END:VEVENT
BEGIN:VEVENT
UID:v16-0250@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271015
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: ASBMR 2027 Annual Meeting\, October 15-18\, 2027\, Metro Toronto Convention Centre\, Toronto\, Ontario\, Canada. World's largest bone and mineral research meeting. [2026-09-23 conference re-source] Re-sourced from bare homepage to deeper dated organizer page\; date confirmed hard. [2026-09-27 link audit] Prior /meetings/future-asbmr-meetings URL now returns a genuine 404 (page removed by organizer)\; repl\nDate quality: hard (2027-10-15)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0250\nSource: https://www.asbmr.org/Annual-Meeting/Future-Meetings
END:VEVENT
BEGIN:VEVENT
UID:v16-0251@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271207
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: San Antonio Breast Cancer Symposium (50th)\, December 7–10\, 2027\, San Antonio\, Texas. Breast cancer research symposium.\nDate quality: hard (2027-12-07)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0251\nSource: https://sabcs.org/media/future-symposia/
END:VEVENT
BEGIN:VEVENT
UID:v16-0252@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270115
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Inaugural ESMO Genitourinary Cancers Asia 2027\, January 15-17 2027\, Kerry Hotel\, Hong Kong SAR\, China. GU oncology (prostate\, bladder\, kidney\, testicular). Source: esmo.org meeting calendar (organizer-owned\, verified 2026-09-18\; dates corroborated by ESMO-produced announcement video).\nDate quality: hard (2027-01-15)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0252\nSource: https://www.esmo.org/meeting-calendar/esmo-genitourinary-cancers-asia-2027
END:VEVENT
BEGIN:VEVENT
UID:v16-0253@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270120
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Inaugural Complex Coronary Summit\, January 20-22 2027\, Fontainebleau Miami Beach\, Miami Beach\, FL\; merging CTO Plus and Interventional Complications (CRF).\nDate quality: hard (2027-01-20)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0253\nSource: https://cto2025.crfconferences.com/cto-hotel
END:VEVENT
BEGIN:VEVENT
UID:v16-0254@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270222
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: THT 2027\, Technology and Heart Failure Therapeutics\, February 22-24 2027\, Omni Boston Hotel at the Seaport\, Boston\, MA (CRF).\nDate quality: hard (2027-02-22)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0254\nSource: https://fellows2024.crfconferences.com/contact-us
END:VEVENT
BEGIN:VEVENT
UID:v16-0255@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270503
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Philadelphia\, PA and online\; premier gene and cell therapy meeting\nDate quality: hard (2027-05-03)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0255\nSource: https://www.asgct.org/events-meetings/2027-annual-meeting
END:VEVENT
BEGIN:VEVENT
UID:v16-0256@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271103
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: National Harbor\, MD\; Nov 3-7\, 2027\nDate quality: hard (2027-11-03)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0256\nSource: https://www.sitcancer.org/edu/41st-annual-meeting/archive
END:VEVENT
BEGIN:VEVENT
UID:v16-0257@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270316
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: 21st International Conference on Alzheimer's and Parkinson's Diseases and Related Disorders (AD/PD 2027)\, March 16-20 2027\, Barcelona\, Spain and online (hybrid). Source: official AD/PD 2027 site (Kenes)\, press information page (organizer-verified 2026-09-18).\nDate quality: hard (2027-03-16)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0257\nSource: https://adpd.kenes.com/press-information/
END:VEVENT
BEGIN:VEVENT
UID:v16-0258@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270612
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Gothenburg\, Sweden\; overarching theme 'Transforming Neurology: Embracing Every Brain'\nDate quality: hard (2027-06-12)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0258\nSource: https://www.ean.org/congress2027
END:VEVENT
BEGIN:VEVENT
UID:v16-0259@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270409
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Stockholm\, Sweden\; infectious diseases and clinical microbiology congress\; opening ceremony 10.04.2027\nDate quality: hard (2027-04-09)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0259\nSource: https://www.escmid.org/congress-events/escmid-global/about/general-information/
END:VEVENT
BEGIN:VEVENT
UID:v16-0260@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270616
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: EASL Congress 2027\, June 16–19 2027\, ExCeL London\, London\, United Kingdom (+ online). Four-day congress\; abstract submission and registration open 28 Sep 2026\; abstract deadline 19 Jan 2027. (Third-party 18–19 Jun adjudicated against organizer.)\n[2026-09-23 correction] The cited EASL welcome-message page (https://www.easlcongress.eu/2027-welcome-message/) now returns dead on probe (page removed/re\nDate quality: hard (2027-06-16)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0260\nSource: https://www.easlcongress.eu/
END:VEVENT
BEGIN:VEVENT
UID:v16-0261@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270712
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Geneva\, Switzerland and virtual\; dates updated 18 Feb 2026 (was 11-15 July)\nDate quality: hard (2027-07-12)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0261\nSource: https://www.iasociety.org/news-release/ias-2027-top-hiv-science-meeting-comes-global-health-hub-geneva
END:VEVENT
BEGIN:VEVENT
UID:v16-0262@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271024
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: CHEST 2027 Annual Meeting\, October 24-27 2027\, Vancouver\, BC\, Canada\; pulmonary\, critical care and sleep medicine. Source: chestnet.org future annual meeting dates (organizer-owned\, verified 2026-09-18\; dates subject to change per CHEST).\nDate quality: hard (2027-10-24)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0262\nSource: https://www.chestnet.org/learning-and-events/events/chest-annual-meeting
END:VEVENT
BEGIN:VEVENT
UID:v16-0263@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270502
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: San Diego\, CA\; premier global eye and vision research meeting\nDate quality: hard (2027-05-02)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0263\nSource: https://www.arvo.org/news/terri-young-2026-2027-arvo-president
END:VEVENT
BEGIN:VEVENT
UID:v16-0264@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271112
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Las Vegas\, NV (Venetian Expo & Hotel)\; Subspecialty Day Nov 12-13\nDate quality: hard (2027-11-12)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0264\nSource: https://www.aao.org/annual-meeting/past-and-future-meetings
END:VEVENT
BEGIN:VEVENT
UID:v16-0265@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270319
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: San Francisco\, CA (Moscone Center)\; 85th edition\nDate quality: hard (2027-03-19)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0265\nSource: https://assets.ctfassets.net/1ny4yoiyrqia/6q27HOlexxkUKnBkBzrknt/b7d680e0f4ce0c13c240268d9a02e87b/am27-exhibitor-prospectus.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-0266@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270513
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Heart Rhythm Society annual meeting\; organizer homepage states Heart Rhythm 2027 will be held May 13-16\, 2027 in San Francisco\, CA.\n[2026-09-23 conference re-source] Re-sourced from bare homepage to dated organizer events page\; date confirmed hard.\nDate quality: hard (2027-05-13)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0266\nSource: http://hrsonline.org/events/
END:VEVENT
BEGIN:VEVENT
UID:v16-0267@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270924
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Charlotte\, NC\; heart failure science\, research\, management and late-breaking clinical research\nDate quality: hard (2027-09-24)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0267\nSource: https://hfsa.org/hfsa-annual-scientific-meeting-2027
END:VEVENT
BEGIN:VEVENT
UID:v16-0268@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270518
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Paris\, France (Palais des Congrès)\; world-leading interventional cardiology course\, 50 years of coronary interventions\nDate quality: hard (2027-05-18)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0268\nSource: https://www.pcronline.com/Courses/EuroPCR/about
END:VEVENT
BEGIN:VEVENT
UID:v16-0269@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270605
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Seattle\, WA\; joint annual meeting of AST and ASTS\; scientific sessions begin June 5 Distinct conference from ENDO 2027 (separate event\, separate organizer)\; shares only the start date 2027-06-05 — not a duplicate.\nDate quality: hard (2027-06-05)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0269\nSource: https://www.asts.org/events-meetings/events-landing/2027/06/05/default-calendar/american-transplant-congress-(atc)-2027
END:VEVENT
BEGIN:VEVENT
UID:v16-0270@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270219
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: New Orleans\, LA\; leading allergy/immunology annual meeting\nDate quality: hard (2027-02-19)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0270\nSource: https://annualmeeting.aaaai.org/attendee/future-dates-locations
END:VEVENT
BEGIN:VEVENT
UID:v16-0271@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270413
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Minneapolis\, MN (Minneapolis Convention Center)\; medical genetics/genomics meeting\n[2026-09-23 conference re-source] Re-sourced to deeper dated organizer-hosted document\; date confirmed hard.\nDate quality: hard (2027-04-13)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0271\nSource: https://cdn.asp.events/CLIENT_ACMG_A41B0E50_05F7_BDBC_57979A443F6299C5/sites/ACGM-2026/media/libraries/PDF-Documents/2027-ACMG-Industry-Satellite-Symposia-Guidelines-and-Terms.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-0272@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270131
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: San Diego\, CA (Manchester Grand Hyatt)\; largest international lysosomal/rare disease research meeting\; 2\,000+ attendees from 50+ countries\nDate quality: hard (2027-01-31)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0272\nSource: https://worldsymposia.org/worldsymposium-attendees/
END:VEVENT
BEGIN:VEVENT
UID:v16-0273@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270217
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Orlando\, FL (Orlando World Center Marriott)\; pre-conference Feb 16\; hematopoietic cell transplantation\, cellular and gene therapy\nDate quality: hard (2027-02-17)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0273\nSource: https://cibmtr.org/CIBMTR/Meetings/Tandem-Meetings
END:VEVENT
BEGIN:VEVENT
UID:v16-0274@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270831
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Dublin\, Ireland (Dublin Convention Centre)\; inherited metabolic disorders\; theme: Complexity - Diversity - Inclusion\nDate quality: hard (2027-08-31)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0274\nSource: https://www.ssiem.org/index.php?option=com_content&view=article&id=110&catid=24
END:VEVENT
BEGIN:VEVENT
UID:v16-0275@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270521
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Los Angeles\, CA\; ob-gyn clinical and scientific meeting\nDate quality: hard (2027-05-21)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0275\nSource: https://annualmeeting.acog.org/about-acsm/
END:VEVENT
BEGIN:VEVENT
UID:v16-0276@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270430
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Minneapolis\, MN (98th meeting)\; premier pediatric research meeting (AAP/APA/APS/SPR)\nDate quality: hard (2027-04-30)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0276\nSource: https://www.pas-meeting.org/2027-key-dates/
END:VEVENT
BEGIN:VEVENT
UID:v16-0277@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270219
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: San Francisco\, CA (Moscone West Convention Center) Distinct conference from AAAAI 2027 Annual Meeting (American Academy of Allergy\, Asthma & Immunology) (separate event\, separate organizer)\; shares only the start date 2027-02-19 — not a duplicate.\nDate quality: hard (2027-02-19)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0277\nSource: https://www.ors.org/futureannualmeetings/
END:VEVENT
BEGIN:VEVENT
UID:v16-0278@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270603
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: 64th ERA Congress (European Renal Association)\, June 3-6 2027\, Rotterdam\, Netherlands (live + virtual). Source: ERA Glasgow 2026 event page (era-online.org)\, Road to Rotterdam 2027 section\, organizer-confirmed 2026-09-18.\nDate quality: hard (2027-06-03)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0278\nSource: https://www.era-online.org/events/glasgow-2026/
END:VEVENT
BEGIN:VEVENT
UID:v16-0279@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270303
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: AAOS 2027 Annual Meeting\, March 3-6 2027 (Wednesday-Saturday)\, The Venetian Convention & Expo Center\, Las Vegas\, Nevada. Source: AAOS Future Meetings page on aaos.org (organizer-owned\, verified 2026-09-18). [2026-09-23 re-source] AAOS CDN bot-blocks direct curl (RemoteDisconnected)\; organizer content verified via search-index crawl (~14h): 'AAOS 2027 will take place March 3-6\, 2027 (Wednesday to S\nDate quality: hard (2027-03-03)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0279\nSource: https://www.aaos.org/annual/attend/future-meetings/
END:VEVENT
BEGIN:VEVENT
UID:v16-0280@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270303
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Copenhagen\, Denmark\; leading IBD congress Distinct conference from AAOS 2027 Annual Meeting (American Academy of Orthopaedic Surgeons) (separate event\, separate organizer)\; shares only the start date 2027-03-03 — not a duplicate.\nDate quality: hard (2027-03-03)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0280\nSource: https://ecco-ibd.eu/congress-events/event-calendar
END:VEVENT
BEGIN:VEVENT
UID:v16-0281@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270331
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Orlando\, FL\; obesity medicine clinical conference\nDate quality: hard (2027-03-31)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0281\nSource: https://obesitymedicine.org/education/annual-conference/
END:VEVENT
BEGIN:VEVENT
UID:v16-0282@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270321
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: MDA Clinical & Scientific Conference 2027\, March 21-24 2027\, Rosen Shingle Creek\, Orlando\, Florida. Source: MDA press release (organizer-owned\, verified 2026-09-18).\nDate quality: hard (2027-03-21)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0282\nSource: https://www.mda.org/press-releases/registration-open-for-2027-mda-clinical-scientific-conference-showcasing-rapid-advances-in
END:VEVENT
BEGIN:VEVENT
UID:v16-0283@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270904
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Maastricht\, Netherlands (MECC)\; pathology/diagnostics relevant to oncology biomarkers\nDate quality: hard (2027-09-04)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0283\nSource: https://www.espcongress.org/future-congresses/
END:VEVENT
BEGIN:VEVENT
UID:v16-0284@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270321
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: San Diego\, CA\; HIV/hepatitis/SARS-CoV-2 research\; organizer notes dates preliminary and subject to change Distinct conference from MDA Clinical & Scientific Conference 2027 (Muscular Dystrophy Association) (separate event\, separate organizer)\; shares only the start date 2027-03-21 — not a duplicate.\nDate quality: hard (2027-03-21)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0284\nSource: https://www.croiconference.org/about/croi-2027-preliminary-important-dates-and-deadlines/
END:VEVENT
BEGIN:VEVENT
UID:v16-0285@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270121
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: New Orleans\, LA\; IBD research and care Distinct conference from ASCO Gastrointestinal Cancers Symposium (separate event\, separate organizer)\; shares only the start date 2027-01-21 — not a duplicate.\nDate quality: hard (2027-01-21)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0285\nSource: https://gastro.org/news/registration-is-open-for-the-2027-crohns-colitis-congress/
END:VEVENT
BEGIN:VEVENT
UID:v16-0286@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270318
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Estoril\, Portugal (also online)\; ERS basic-science meeting\; flagship ERS International Congress 2027 dates not yet announced\nDate quality: hard (2027-03-18)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0286\nSource: https://www.ersnet.org/news-and-features/congress-category/
END:VEVENT
BEGIN:VEVENT
UID:v16-0287@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270611
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Helsinki\, Finland\; world's largest allergy/clinical immunology congress\; immunotherapy\, biologics\, food allergy\nDate quality: hard (2027-06-11)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0287\nSource: https://www.eaaci.org/eaaci-events/eaaci-congresses/upcoming-congress.html
END:VEVENT
BEGIN:VEVENT
UID:v16-0288@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270311
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: EAACI Skin Allergy Meeting (SAM) 2027\, March 11-13 2027\, Paris\, France. Focused meeting on skin allergy (urticaria\, angioedema\, atopic/contact dermatitis\, drug hypersensitivity)\, organized with ESCD and ISAD. Source: dedicated SAM 2027 page on eaaci.org (organizer-owned\, verified 2026-09-18).\nDate quality: hard (2027-03-11)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0288\nSource: https://eaaci.org/events_meetings/sam-2027-2/
END:VEVENT
BEGIN:VEVENT
UID:v16-0289@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270401
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: APASL Annual Meeting 2027 (36th)\, April 1-4 2027\, Sydney\, Australia. Source: official APASL 2027 congress site (cited by APASL).\n[2026-09-23 correction] A prior note claimed a re-source to a deeper dated organizer page\, but the source URL was never actually changed and the APASL future-meetings page now returns 404 (removed). Event retained: dates browser-verified 2026-09-18 and re-verified 2026-0\nDate quality: hard (2027-04-01)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0289\nSource: https://www.apasl2027.org/
END:VEVENT
BEGIN:VEVENT
UID:v16-0290@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270110
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: San Francisco\, CA\; derm industry/business-development forum for innovators and investors\nDate quality: hard (2027-01-10)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0290\nSource: https://advancing-derm.org/platform/conferences/dermatology-summit-2027/
END:VEVENT
BEGIN:VEVENT
UID:v16-0291@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270225
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: 28th European Congress on Gynaecological Oncology (ESGO 2027)\, February 25-27 2027\, London\, United Kingdom\, Excel London. Theme: Bridging Science and Care. Source: official ESGO Congress welcome letter (congress.esgo.org)\, organizer-confirmed 2026-09-18.\nDate quality: hard (2027-02-25)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0291\nSource: https://congress.esgo.org/about/welcome-letter/
END:VEVENT
BEGIN:VEVENT
UID:v16-0292@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270306
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Washington\, DC\; interventional cardiology with innovation/medtech sessions\nDate quality: hard (2027-03-06)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0292\nSource: https://crtmeeting.org/attend-crt/about-crt/
END:VEVENT
BEGIN:VEVENT
UID:v16-0293@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271114
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: McCormick Place\, Chicago\; world's largest radiology/imaging meeting\; imaging diagnostics and AI\nDate quality: hard (2027-11-14)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0293\nSource: https://www.rsna.org/-/media/files/rsna/annual-meeting/preparing-to-attend/travel/int901-international-visa-letter-updates-for-2027_interactive.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-0294@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270309
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Miami\, FL\; Jefferies flagship biotech investor conference (presentations & meetings)\nDate quality: hard (2027-03-09)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0294\nSource: https://jefferies.com/wp-content/uploads/sites/4/2026/08/8_21_26_Jefferies_2026_Conference_Summit_Calendar.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-0295@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270501
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Washington\, DC (and online)\; AAN 79th Annual Meeting\nDate quality: hard (2027-05-01)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0295\nSource: https://www.aan.com/events/upcoming-events
END:VEVENT
BEGIN:VEVENT
UID:v16-0296@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270520
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Stockholm\, Sweden (Waterfront Congress Centre)\; psoriasis-focused\nDate quality: hard (2027-05-20)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0296\nSource: https://www.ifpa-pso.com/ifpa-conference-2027
END:VEVENT
BEGIN:VEVENT
UID:v16-0297@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271206
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Dublin\, Ireland\; host: Irish MND Association\nDate quality: hard (2027-12-06)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0297\nSource: https://symposium.mndassociation.org/about-the-event/future-dates/
END:VEVENT
BEGIN:VEVENT
UID:v16-0298@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270409
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: San Diego\, CA\; American Association of Neurological Surgeons\; theme 'Navigating the Impossible' Distinct conference from ESCMID Global 2027 (37th Congress of ESCMID) (separate event\, separate organizer)\; shares only the start date 2027-04-09 — not a duplicate.\nDate quality: hard (2027-04-09)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0298\nSource: https://www.aans.org/annual-meeting/meeting-dates/
END:VEVENT
BEGIN:VEVENT
UID:v16-0299@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270312
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Eighth Annual Global Summit on Immunotherapies for Hematologic Malignancies\, March 12-13 2027 (Fri-Sat)\, JW Marriott Brickell\, Miami\, FL\; Miami Cancer Institute / Baptist Health South Florida CME event (leukemia\, lymphoma\, multiple myeloma\, CAR-T\, transplant). Source: 2027 Summit exhibitor prospectus PDF on cmeonline.baptisthealth.net (organizer-issued\, verified 2026-09-18).\nDate quality: hard (2027-03-12)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0299\nSource: https://cmeonline.baptisthealth.net/sites/default/files/2027%20Immunotherapy%20Summit%20Prospectus.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-0301@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270224
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Toronto\, ON\, Canada (Sheraton Centre Toronto Hotel)\; interventional oncology\nDate quality: hard (2027-02-24)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0301\nSource: https://www.sio-central.org/Events
END:VEVENT
BEGIN:VEVENT
UID:v16-0302@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270115
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Transplant AI Symposium 2027\, January 15-16 2027\, Arizona Biltmore\, Scottsdale\, AZ. Mayo Clinic CME course (in-person and livestream). Source: ce.mayo.edu course page (search-engine-verified 2026-09-18\; direct curl probes get bot-blocked 403). Distinct conference from ESMO Genitourinary Cancers Asia 2027 (separate event\, separate organizer)\; shares only the start date 2027-01-15 — not a duplicate.\nDate quality: hard (2027-01-15)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0302\nSource: https://ce.mayo.edu/transplant-medicine/content/transplant-ai-symposium-2027
END:VEVENT
BEGIN:VEVENT
UID:v16-0303@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270926
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Prague\, Czech Republic\; International Transplant Congress\, theme 'Mens et Machina'\nDate quality: hard (2027-09-26)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0303\nSource: https://esot.org/esot-events/esot-congress-2027/
END:VEVENT
BEGIN:VEVENT
UID:v16-0304@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270301
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Birmingham\, UK (Birmingham Conference & Events Centre)\; microbiome science and therapeutics\nDate quality: hard (2027-03-01)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0304\nSource: https://www.bsg.org.uk/events/bsg-gut-microbiota-for-health-conference-2027
END:VEVENT
BEGIN:VEVENT
UID:v16-0305@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270214
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: 6th ESH Scientific Workshop on Haematological Tumour Microenvironment (#ESHMICRO2027)\, starting Feb 14 2027\, London\, UK. Source: ESH-issued save-the-date campaign archive (Mailchimp\, sent from esh.org).\nDate quality: hard (2027-02-14)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0305\nSource: https://mailchi.mp/esh.org/cmlmpn2027_savethedate-5900234
END:VEVENT
BEGIN:VEVENT
UID:v16-0306@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270828
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Amsterdam\, Netherlands (RAI Amsterdam)\; ILAE/IBE Source upgraded 2026-09-18 to ILAE official congress page directly exposing dates and venue (Amsterdam\, Aug 28-Sep 1 2027).\nDate quality: hard (2027-08-28)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0306\nSource: https://www.ilae.org/congresses/37th-international-epilepsy-congress/section/sectionid/3
END:VEVENT
BEGIN:VEVENT
UID:v16-0307@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270128
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Tunis\, Tunisia (Radisson Blu Hotel & Convention Center)\; CRF regional structural/interventional cardiology meeting\nDate quality: hard (2027-01-28)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0307\nSource: https://assets.crfconnect.com/meetings/tctafrica2027/resources/TCT_AFRICA_2027_Industry_Brochure.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-0308@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270317
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: TCT Plus LATAM Valves 2027 (Structural Heart Summit)\, March 17-19 2027\, WTC Events Center\, Sao Paulo\, Brazil (CRF).\nDate quality: hard (2027-03-17)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0308\nSource: https://fellows2024.crfconferences.com/contact-us
END:VEVENT
BEGIN:VEVENT
UID:v16-0309@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270402
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: San Diego\, CA\; anterior segment/cataract-refractive surgery\; ASOA meeting co-located Distinct conference from AACR Annual Meeting 2027 (separate event\, separate organizer)\; shares only the start date 2027-04-02 — not a duplicate.\nDate quality: hard (2027-04-02)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0309\nSource: https://annualmeeting.ascrs.org/for-speakers/important-dates
END:VEVENT
BEGIN:VEVENT
UID:v16-0310@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270515
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Washington\, DC (and online)\; AGA/ASGE/AASLD/SSAT\; exhibit hall May 16-18\nDate quality: hard (2027-05-15)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0310\nSource: https://news.ddw.org/news/save-the-date-for-ddw-2027/
END:VEVENT
BEGIN:VEVENT
UID:v16-0311@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270522
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: ASCRS Annual Scientific Meeting\, May 22-25 2027\, New Orleans\, LA (Ernest N. Morial Convention Center\; HQ hotel Hilton New Orleans Riverside)\; tripartite meeting. Source: ASCRS Future Annual Meetings page (organizer-owned\, verified 2026-09-18).\nDate quality: hard (2027-05-22)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0311\nSource: https://fascrs.org/Web/Web/My-ASCRS/Meetings-Events/Future-Annual-Meetings.aspx
END:VEVENT
BEGIN:VEVENT
UID:v16-0312@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270609
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Berlin\, Germany (Messe Berlin)\; 80th anniversary congress of rheumatology\nDate quality: hard (2027-06-09)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0312\nSource: http://congress.eular.org/about
END:VEVENT
BEGIN:VEVENT
UID:v16-0313@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270626
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Vancouver\, Canada (Vancouver Convention Centre)\; thrombosis\, hemostasis and vascular biology\nDate quality: hard (2027-06-26)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0313\nSource: https://www.isth.org/page/ISTHCongresses
END:VEVENT
BEGIN:VEVENT
UID:v16-0314@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270622
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Chicago\, IL\; 3-meeting structure: Applied & Environmental Microbiology\, Health\, Mechanism Discovery\nDate quality: hard (2027-06-22)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0314\nSource: http://asm.org/events/asm-microbe/home
END:VEVENT
BEGIN:VEVENT
UID:v16-0315@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270514
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: San Diego\, CA (Marriott Marquis San Diego Marina)\; abstracts due Dec 1\, 2026\nDate quality: hard (2027-05-14)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0315\nSource: https://pro.aace.com/education-and-event/product/aace-annual-meeting-2027
END:VEVENT
BEGIN:VEVENT
UID:v16-0316@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270618
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: ADA Scientific Sessions 2027\, June 18-21 2027 (Friday June 18 10:30 a.m. ET start\, Monday June 21 4:15 p.m. ET close)\, Walter E. Washington Convention Center\, Washington DC. Source: ADA official Scientific Sessions FAQ page (organizer-owned\, verified 2026-09-18).\nDate quality: hard (2027-06-18)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0316\nSource: https://professional.diabetes.org/scientific-sessions/frequently-asked-questions
END:VEVENT
BEGIN:VEVENT
UID:v16-0317@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270514
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: New Orleans\, LA\; May 14-15 pre-conference\, May 16-19 main conference Distinct conference from AACE Annual Meeting 2027 (American Association of Clinical Endocrinology) (separate event\, separate organizer)\; shares only the start date 2027-05-14 — not a duplicate.\nDate quality: hard (2027-05-14)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0317\nSource: http://site.thoracic.org/conference/attendees/future-conferences
END:VEVENT
BEGIN:VEVENT
UID:v16-0318@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271111
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: ACAAI 2027 Annual Scientific Meeting\, November 11-15 2027\, Nashville\, Tennessee. Source: ACAAI annual-meeting future-dates page (browser-verified 2026-09-18\; curl probe failed to connect). [2026-09-23 source check] Source unreachable from this network (TLS handshake timeout on both passes — not confirmed dead)\; organizer content seen live in search-index crawls within the last 14 days. Flagged for\nDate quality: hard (2027-11-11)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0318\nSource: https://annualmeeting.acaai.org/future_meeting_dates.cfm
END:VEVENT
BEGIN:VEVENT
UID:v16-0319@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270222
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Paris\, France (Palais des Congres)\; early-phase drug development congress Distinct conference from THT 2027 (Technology and Heart Failure Therapeutics) (separate event\, separate organizer)\; shares only the start date 2027-02-22 — not a duplicate.\nDate quality: hard (2027-02-22)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0319\nSource: https://dam.esmo.org/image/upload/v1785409882/ESMO-TAT-2027-Industry-Guidelines_wbmntv.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-0320@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270317
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: European Lung Cancer Congress 2027\, March 17-20 2027\, Munich\, Germany (Messe München) and online\; ESMO/IASLC joint thoracic oncology congress. Source: ELCC 2027 Industry Guidelines PDF on dam.esmo.org (organizer-issued\, verified 2026-09-18). Distinct conference from TCT Plus LATAM Valves 2027 — Structural Heart Summit (CRF) (separate event\, separate organizer)\; shares only the start date 2027-03-1\nDate quality: hard (2027-03-17)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0320\nSource: https://dam.esmo.org/image/upload/v1784884466/ELCC-2027-Industry-Guidelines_o6kgid.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-0321@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270624
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Rotterdam\, Netherlands\; in-person only\; supportive care in cancer\nDate quality: hard (2027-06-24)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0321\nSource: https://mascc.org/annualmeeting2027/
END:VEVENT
BEGIN:VEVENT
UID:v16-0322@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270503
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Orlando\, FL\; medical publications professionals Distinct conference from ASGCT 30th Annual Meeting 2027 (separate event\, separate organizer)\; shares only the start date 2027-05-03 — not a duplicate.\nDate quality: hard (2027-05-03)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0322\nSource: http://www.ismpp.org/annual-meeting
END:VEVENT
BEGIN:VEVENT
UID:v16-0323@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270523
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Denver\, CO (Colorado Convention Center)\, May 23-26 2027\; health economics and outcomes research. Source updated 2026-09-18: ISPOR official calendar on ispor.org directly exposes 23-26 May 2027 Denver dates (registration page lacks dates).\nDate quality: hard (2027-05-23)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0323\nSource: https://www.ispor.org/conferences-education/calendar/event
END:VEVENT
BEGIN:VEVENT
UID:v16-0324@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270430
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: IMMUNOLOGY2027 (AAI 110th Annual Meeting)\, April 30-May 4 2027\, Los Angeles\, California. Source: AAI future-meetings page (browser-verified 2026-09-18\; curl probe got bot-blocked 403). Distinct conference from PAS 2027 (Pediatric Academic Societies Meeting) (separate event\, separate organizer)\; shares only the start date 2027-04-30 — not a duplicate.\nDate quality: hard (2027-04-30)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0324\nSource: http://www.aai.org/Meetings/Future_Meeting.html
END:VEVENT
BEGIN:VEVENT
UID:v16-0325@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270128
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: STS 63rd Annual Meeting\, January 28-31 2027\, San Diego\, CA. Source: STS event page (browser-verified 2026-09-18\; curl probe failed to connect). Distinct conference from TCT Plus Africa 2027 (CRF) (separate event\, separate organizer)\; shares only the start date 2027-01-28 — not a duplicate.\nDate quality: hard (2027-01-28)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0325\nSource: https://www.sts.org/calendar-of-events/63rd-sts-annual-meeting
END:VEVENT
BEGIN:VEVENT
UID:v16-0326@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270121
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Steamboat Springs\, CO\; per 2027 exhibitor prospectus Distinct conference from ASCO Gastrointestinal Cancers Symposium (separate event\, separate organizer)\; shares only the start date 2027-01-21 — not a duplicate.\nDate quality: hard (2027-01-21)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0326\nSource: https://vesurgery.org/wp-content/uploads/2026/06/vess-2027-exhibitor-prospectus.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-0327@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270501
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: AATS 107th Annual Meeting\, May 1-4 2027\, Los Angeles Convention Center\, Los Angeles\, CA. Source: AATS future-annual-meetings page (previously cited a vendor prospectus). Distinct conference from AAN Annual Meeting 2027 (79th\, American Academy of Neurology) (separate event\, separate organizer)\; shares only the start date 2027-05-01 — not a duplicate.\nDate quality: hard (2027-05-01)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0327\nSource: https://www.aats.org/future-annual-meetings
END:VEVENT
BEGIN:VEVENT
UID:v16-0328@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270601
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: New Orleans\, LA (The Roosevelt New Orleans)\; endovascular medicine\; organized by Cardiovascular Institute of the South\nDate quality: hard (2027-06-01)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0328\nSource: https://www.cardio.com/news/ncvh-continues-to-draw-a-crowd-as-1400-attend-the-27th-annual-conference-at-the-roosevelt/
END:VEVENT
BEGIN:VEVENT
UID:v16-0329@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270122
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: GEST MSK 2027 (5th edition)\, January 22-23 2027\; Paris\, France (Marriott Rive Gauche\, 75014 Paris). MSK embolization specialty meeting (knee OA GAE\, adhesive capsulitis\, plantar fasciitis\, tendinopathies). Dates: organizer 'save the date' announcement (Global Embolization Symposium & Technologies official LinkedIn channel\, posted ~Sep 2026). Organizer-owned source: https://www.linkedin.com/company\nDate quality: hard (2027-01-22)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0329\nSource: https://thegestgroup.com/annual-msk-meeting/
END:VEVENT
BEGIN:VEVENT
UID:v16-0330@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270614
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Bilbao\, Spain (Bilbao Exhibition Centre)\; basic\, preclinical and translational cancer research\nDate quality: hard (2027-06-14)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0330\nSource: https://eacr.org/congress
END:VEVENT
BEGIN:VEVENT
UID:v16-0331@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270411
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Rotterdam Ahoy\, Rotterdam\, Netherlands\; blood/marrow transplantation and cellular therapy\nDate quality: hard (2027-04-11)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0331\nSource: https://www.ebmt.org/events/53rd-annual-meeting-ebmt
END:VEVENT
BEGIN:VEVENT
UID:v16-0332@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270316
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Basel\, Switzerland\; regulatory science / life sciences innovation Distinct conference from AD/PD 2027 (separate event\, separate organizer)\; shares only the start date 2027-03-16 — not a duplicate.\nDate quality: hard (2027-03-16)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0332\nSource: https://www.diaglobal.org/en/flagship/dia-europe-2027
END:VEVENT
BEGIN:VEVENT
UID:v16-0333@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270628
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: San Diego\, CA\; per DIA global events calendar\nDate quality: hard (2027-06-28)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0333\nSource: https://www.diaglobal.org/en/general/global-events
END:VEVENT
BEGIN:VEVENT
UID:v16-0334@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270501
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: DIA China Annual Meeting 2027\, starting May 1\, 2027. End date and host city not published on the DIA events calendar as of September 2026\; China’s regulatory-industry annual meeting. (Stayed hard: start day is organizer-printed.) Distinct conference from AAN Annual Meeting 2027 (79th\, American Academy of Neurology) (separate event\, separate organizer)\; shares only the start date 2027-05-01 — not a\nDate quality: hard (2027-05-01)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0334\nSource: https://www.diaglobal.org/en/general/global-events
END:VEVENT
BEGIN:VEVENT
UID:v16-0335@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270303
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Vienna\, Austria (Austria Center Vienna)\; onsite & online Distinct conference from AAOS 2027 Annual Meeting (American Academy of Orthopaedic Surgeons) (separate event\, separate organizer)\; shares only the start date 2027-03-03 — not a duplicate.\nDate quality: hard (2027-03-03)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0335\nSource: https://www.myesr.org/congress/about-ecr/
END:VEVENT
BEGIN:VEVENT
UID:v16-0336@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270301
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Rosen Shingle Creek\, Orlando\, FL\; clinical research operations\; Cambridge Healthtech Institute Distinct conference from BSG Gut Microbiota for Health Conference 2027 (British Society of Gastroenterology) (separate event\, separate organizer)\; shares only the start date 2027-03-01 — not a duplicate.\nDate quality: hard (2027-03-01)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0336\nSource: https://www.scopesummit.com/Clinical-Trial-Delivery
END:VEVENT
BEGIN:VEVENT
UID:v16-0337@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270317
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Vienna\, Austria\; primary therapy of early breast cancer\; consensus manuscript Distinct conference from TCT Plus LATAM Valves 2027 — Structural Heart Summit (CRF) (separate event\, separate organizer)\; shares only the start date 2027-03-17 — not a duplicate.\n[2026-09-23 conference re-source] URL unchanged: homepage is the dedicated 2027 event site and prints the dates\; date confirmed hard.\n[2026-09-\nDate quality: hard (2027-03-17)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0337\nSource: https://www.sg-bcc.org/
END:VEVENT
BEGIN:VEVENT
UID:v16-0338@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270228
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Omni La Costa Resort & Spa\, Carlsbad\, CA Distinct conference from AACR Immuno-Oncology 2027 (separate event\, separate organizer)\; shares only the start date 2027-02-28 — not a duplicate.\nDate quality: hard (2027-02-28)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0338\nSource: https://abdominalradiology.org/sar-subpages/annual-meeting/
END:VEVENT
BEGIN:VEVENT
UID:v16-0339@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270320
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: SIR 2027 Annual Scientific Meeting\, March 20-24\, 2027\, Los Angeles. [2026-09-23 conference re-source] Re-sourced from bare homepage to deeper dated organizer page\; date confirmed hard. [2026-09-27 link audit] Prior aaStatic.asp URL now returns "link expired" (retired by organizer)\; replaced with sirmeeting.org\, which now serves as the official SIR 2027 event page\, re-verified in-browser: confirms \nDate quality: hard (2027-03-20)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0339\nSource: https://www.sirmeeting.org/
END:VEVENT
BEGIN:VEVENT
UID:v16-0340@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270819
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Singapore (joint with SGCR-WIRES 2027)\; "Inspiring Excellence in Radiology"\nDate quality: hard (2027-08-19)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0340\nSource: http://abdominalradiology-asia.org/annual-meeting/acar2027-in-singapore/
END:VEVENT
BEGIN:VEVENT
UID:v16-0341@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270413
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Salt Lake City\, UT\; radiology training and practice in the AI era Distinct conference from ACMG 2027 Annual Clinical Genetics Meeting (American College of Medical Genetics and Genomics) (separate event\, separate organizer)\; shares only the start date 2027-04-13 — not a duplicate.\nDate quality: hard (2027-04-13)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0341\nSource: https://www.apdr.org/annual-meeting
END:VEVENT
BEGIN:VEVENT
UID:v16-0342@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270218
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: ACRO 2027: The Radiation Oncology Summit\, February 18-21 2027\; Las Vegas\, Nevada. American College of Radiation Oncology annual meeting. Source: ACRO official annual-meeting page (organizer-owned\, verified 2026-09-18). [2026-09-23 source check] Source unreachable from this network (connection reset on both passes — not confirmed dead)\; organizer content seen live in search-index crawls within the \nDate quality: hard (2027-02-18)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0342\nSource: https://acro.org/page/annualmeeting
END:VEVENT
BEGIN:VEVENT
UID:v16-0343@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270115
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: 50th ASN Annual Meeting\, January 15-17 2027\; Hilton Head Island\, SC. American Society of Neuroimaging annual meeting (neuroimaging education and certification). Source: ASN official homepage (organizer-owned\, verified 2026-09-18). Distinct conference from ESMO Genitourinary Cancers Asia 2027 (separate event\, separate organizer)\; shares only the start date 2027-01-15 — not a duplicate.\n[2026-09-23 \nDate quality: hard (2027-01-15)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0343\nSource: http://www.asnweb.org/
END:VEVENT
BEGIN:VEVENT
UID:v16-0344@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270304
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Hyatt Regency Seattle\, Seattle\, WA\; clinical neurophysiology (EEG\, epilepsy\, neuromuscular) Source upgraded 2026-09-18: ACNS 2027 call-for-proposals PDF (organizer) states March 4-7 2027\, Seattle WA.\nDate quality: hard (2027-03-04)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0344\nSource: https://www.acns.org/UserFiles/AM27CallForProposal.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-0345@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270318
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Charleston\, SC\; TTS official section meeting Distinct conference from ERS Lung Science Conference 2027 (European Respiratory Society) (separate event\, separate organizer)\; shares only the start date 2027-03-18 — not a duplicate.\nDate quality: hard (2027-03-18)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0345\nSource: https://tts.org/events/tts-meetings-and-events-calendar
END:VEVENT
BEGIN:VEVENT
UID:v16-0346@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270506
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Chicago\, IL\; TTS official section meeting\nDate quality: hard (2027-05-06)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0346\nSource: https://tts.org/events/tts-meetings-and-events-calendar
END:VEVENT
BEGIN:VEVENT
UID:v16-0347@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270508
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Taipei\, Taiwan\; TTS official section meeting\nDate quality: hard (2027-05-08)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0347\nSource: https://tts.org/events/tts-meetings-and-events-calendar
END:VEVENT
BEGIN:VEVENT
UID:v16-0348@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270511
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Tokyo\, Japan\; TTS official section meeting\nDate quality: hard (2027-05-11)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0348\nSource: https://tts.org/events/tts-meetings-and-events-calendar
END:VEVENT
BEGIN:VEVENT
UID:v16-0349@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270707
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Montreal\, Canada\; TTS official section meeting\nDate quality: hard (2027-07-07)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0349\nSource: https://tts.org/events/tts-meetings-and-events-calendar
END:VEVENT
BEGIN:VEVENT
UID:v16-0350@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271020
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: London\, UK\; TTS official section meeting\nDate quality: hard (2027-10-20)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0350\nSource: https://tts.org/events/tts-meetings-and-events-calendar
END:VEVENT
BEGIN:VEVENT
UID:v16-0351@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270401
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Kuala Lumpur\, Malaysia\; hosted by Malaysian Society of Nephrology (MSN)\; flagship ISN meeting Distinct conference from APASL Annual Meeting 2027 (Asian Pacific Association for the Study of the Liver) (separate event\, separate organizer)\; shares only the start date 2027-04-01 — not a duplicate.\nDate quality: hard (2027-04-01)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0351\nSource: https://www.theisn.org/wcn/
END:VEVENT
BEGIN:VEVENT
UID:v16-0352@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270528
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: APASL STC 2027 Bishkek\, May 28-29 2027. Source: APASL future-meetings page (browser-verified 2026-09-18\; curl probes are blocked with 404). [2026-09-23 source check] Cited URL http://apasl.info/conf/future-meetings/ returns HTTP 404 on both probe passes (page removed) — event retained per policy (events are never removed over URL problems alone\; dates browser-verified 2026-09-18\, v16-0289 re-verif\nDate quality: hard (2027-05-28)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0352\nSource: http://apasl.info/
END:VEVENT
BEGIN:VEVENT
UID:v16-0353@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270625
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: APASL STC 2027 Kaohsiung\, June 25-27 2027. Source: APASL future-meetings page (browser-verified 2026-09-18\; curl probes are blocked with 404). [2026-09-23 source check] Cited URL http://apasl.info/conf/future-meetings/ returns HTTP 404 on both probe passes (page removed) — event retained per policy (events are never removed over URL problems alone\; dates browser-verified 2026-09-18\, v16-0289 re-ve\nDate quality: hard (2027-06-25)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0353\nSource: http://apasl.info/
END:VEVENT
BEGIN:VEVENT
UID:v16-0354@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270723
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: APASL STC 2027 Danang\, July 23-24 2027. Source: APASL future-meetings page (browser-verified 2026-09-18\; curl probes are blocked with 404). [2026-09-23 source check] Cited URL http://apasl.info/conf/future-meetings/ returns HTTP 404 on both probe passes (page removed) — event retained per policy (events are never removed over URL problems alone\; dates browser-verified 2026-09-18\, v16-0289 re-verif\nDate quality: hard (2027-07-23)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0354\nSource: http://apasl.info/
END:VEVENT
BEGIN:VEVENT
UID:v16-0355@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271008
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: APASL STC 2027 Chongqing\, October 8-10 2027. Source: APASL future-meetings page (browser-verified 2026-09-18\; curl probes are blocked with 404). [2026-09-23 source check] Cited URL http://apasl.info/conf/future-meetings/ returns HTTP 404 on both probe passes (page removed) — event retained per policy (events are never removed over URL problems alone\; dates browser-verified 2026-09-18\, v16-0289 re-\nDate quality: hard (2027-10-08)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0355\nSource: http://apasl.info/
END:VEVENT
BEGIN:VEVENT
UID:v16-0356@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270907
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Sydney\, Australia\; pediatric and adolescent oncology (note: ISPN calendar lists Sept 8–11\; SIOP itself says Sept 7–10)\nDate quality: hard (2027-09-07)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0356\nSource: https://siop-online.org/news/siop-2027-sydney-proposals/
END:VEVENT
BEGIN:VEVENT
UID:v16-0357@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270926
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: EANS 2027 Congress\, September 26-30\, 2027\, Basel\, Switzerland. Source: eans.org EANS_Congress page Future Congresses list (organizer-verified 2026-10-01\; direct curl probes get bot-blocked 403). Distinct conference from the ESOT Congress 2027 (Prague\, organ transplantation) — different organizer\, city\, and field.\nDate quality: hard (2027-09-26)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0357\nSource: https://www.eans.org/page/EANS_Congress
END:VEVENT
BEGIN:VEVENT
UID:v16-0358@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271023
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Congress of Neurological Surgeons 2027 Annual Meeting\, October 23–27\, 2027\, Phoenix\, Arizona. Neurosurgery annual meeting.\nDate quality: hard (2027-10-23)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0358\nSource: http://cns.org/meetings/past-and-future-annual-meetings
END:VEVENT
BEGIN:VEVENT
UID:v16-0359@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271031
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: 53rd ISPN Annual Meeting\, October 31–November 4\, 2027\, Taipei\, Taiwan. International pediatric neurosurgery annual meeting.\nDate quality: hard (2027-10-31)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0359\nSource: https://ispnmeeting.org/
END:VEVENT
BEGIN:VEVENT
UID:v16-0360@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270131
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: 50th ASPN Annual Meeting (American Society of Pediatric Neurosurgeons)\, January 31 - February 5\, 2027\, The Ritz-Carlton\, Grand Cayman. Source: ASPN official website 'Save the Date' announcement (aspn.memberclicks.net\, society-owned)\; corroborated by ISPN Global Neurosurgical Calendar (updated Jun 3 2026\, https://ispnmeeting.org/wp-content/uploads/2026/06/ISPN-Global-Neurosurgical-Calendar-2026-202\nDate quality: hard (2027-01-31)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0360\nSource: https://aspn.memberclicks.net/login
END:VEVENT
BEGIN:VEVENT
UID:v16-0361@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270409
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Seattle\, WA (Seattle Convention Center)\, in conjunction with COSM Distinct conference from ESCMID Global 2027 (37th Congress of ESCMID) (separate event\, separate organizer)\; shares only the start date 2027-04-09 — not a duplicate.\nDate quality: hard (2027-04-09)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0361\nSource: https://WWW.ASPO.US/annual-meeting-members
END:VEVENT
BEGIN:VEVENT
UID:v16-0362@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270415
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: ASPNeph 2027 Annual Meeting (American Society of Pediatric Nephrology)\, April 15-17\, 2027\, InterContinental New Orleans\, 444 St. Charles Ave\, New Orleans\, LA. Inaugural standalone meeting. Source: ASPN 2027 prospectus (organizer PDF\, search-engine-verified 2026-09-18\; direct curl probes get bot-blocked 403).\nDate quality: hard (2027-04-15)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0362\nSource: http://aspneph.org/wp-content/uploads/2026/04/2027-Prespectus-V4.27.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-0363@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270511
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: 2027 ASPHO annual conference\, May 11-14\, Palais des congres de Montreal\, Montreal\, Canada\; dates from ASPHO-owned corporate prospectus PDF. Distinct conference from CIIRTA 2027 (20th Congress\, Intl Intestinal Rehabilitation & Transplantation Association) (separate event\, separate organizer)\; shares only the start date 2027-05-11 — not a duplicate.\nDate quality: hard (2027-05-11)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0363\nSource: http://aspho.org/uploads/ASPHO25_Corporate_Prospectus_web_2.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-0364@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270319
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: 42nd Annual EAU Congress (EAU27)\, March 19–22\, 2027\, RAI Amsterdam\, Amsterdam\, The Netherlands. European urology flagship congress. Distinct conference from AAD 2027 Annual Meeting (American Academy of Dermatology) (separate event\, separate organizer)\; shares only the start date 2027-03-19 — not a duplicate.\nDate quality: hard (2027-03-19)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0364\nSource: https://eaucongress.uroweb.org/the-congress/general-information
END:VEVENT
BEGIN:VEVENT
UID:v16-0365@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270625
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Canadian Urological Association annual meeting\, June 25-27 2027\, Halifax Convention Centre\, Halifax\, NS\, Canada. Distinct conference from APASL STC 2027 Kaohsiung (Single Topic Conference: MASLD/MAFLD) (separate event\, separate organizer)\; shares only the start date 2027-06-25 — not a duplicate.\nDate quality: hard (2027-06-25)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0365\nSource: https://www.cua.org/upcoming-events
END:VEVENT
BEGIN:VEVENT
UID:v16-0366@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270110
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: 65th Annual Meeting of the American College of Neuropsychopharmacology\, January 10-13 2027\, San Diego\, California. Distinct conference from Dermatology Summit 2027 (Advancing Innovation in Dermatology) (separate event\, separate organizer)\; shares only the start date 2027-01-10 — not a duplicate.\nDate quality: hard (2027-01-10)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0366\nSource: https://files.constantcontact.com/61d9ccf2601/cdbd0b72-0001-4aef-9ea3-ad7d8b8bfbd3.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-0367@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270623
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: New York Valves 2027 structural heart summit\, June 23-25 2027 (CRF\, in partnership with AATS). Source: CRF organizer site.\nDate quality: hard (2027-06-23)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0367\nSource: http://crf.org/crf/news-and-events/events-calendar
END:VEVENT
BEGIN:VEVENT
UID:v16-0368@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270409
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: IDF Congress 2027\, April 9-12 2027\, Singapore. Note: one third-party supplier page reports April 10-12\; IDF-owned pages report April 9-12. Distinct conference from ESCMID Global 2027 (37th Congress of ESCMID) (separate event\, separate organizer)\; shares only the start date 2027-04-09 — not a duplicate.\nDate quality: hard (2027-04-09)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0368\nSource: https://idf.org/congress-and-events/upcoming-diabetes-events/international-diabetes-federation-world-diabetes-congress-2027/
END:VEVENT
BEGIN:VEVENT
UID:v16-0369@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271026
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: ASHG Annual Meeting 2027\, October 26-30 2027\, Nashville\, TN.\nDate quality: hard (2027-10-26)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0369\nSource: https://www.ashg.org/meetings/future-past/
END:VEVENT
BEGIN:VEVENT
UID:v16-0370@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271015
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: AAP National Conference & Exhibition 2027\, October 15-19 2027\, McCormick Place\, Chicago. Distinct conference from ASBMR 2027 Annual Meeting (separate event\, separate organizer)\; shares only the start date 2027-10-15 — not a duplicate.\nDate quality: hard (2027-10-15)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0370\nSource: https://archive.aapexperience.org/future-dates/
END:VEVENT
BEGIN:VEVENT
UID:v16-0371@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270128
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: ASTS Winter Symposium 2027\, January 28-31 2027\, JW Marriott Orlando Grande Lakes\, Orlando\, FL. Distinct conference from TCT Plus Africa 2027 (CRF) (separate event\, separate organizer)\; shares only the start date 2027-01-28 — not a duplicate.\nDate quality: hard (2027-01-28)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0371\nSource: http://asts.org/events-meetings/winter-symposium
END:VEVENT
BEGIN:VEVENT
UID:v16-0372@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271111
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: 74th STSA Annual Meeting\, November 11-14 2027\, Hyatt Regency Lost Pines Resort & Spa\, Cedar Creek\, TX. Distinct conference from ACAAI 2027 Annual Scientific Meeting (separate event\, separate organizer)\; shares only the start date 2027-11-11 — not a duplicate.\nDate quality: hard (2027-11-11)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0372\nSource: https://stsa.org/meeting/archives/
END:VEVENT
BEGIN:VEVENT
UID:v16-0373@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270414
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: ISHLT 47th Annual Meeting & Scientific Sessions\, April 14-17 2027\, International Convention Centre Sydney\, Sydney\, Australia (preconference day April 13).\nDate quality: hard (2027-04-14)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0373\nSource: https://www.ishlt.org/annual-meeting/other-annual-meetings/future-dates
END:VEVENT
BEGIN:VEVENT
UID:v16-0374@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270127
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: PVRI 2027 Annual Congress\, January 27-31 2027\, Amari Bangkok Hotel & Conference Centre\, Bangkok\, Thailand. Theme: Bridging Science\, Innovation & Care for the Next 20 Years.\n[2026-09-23 conference re-source] Re-sourced from bare homepage to dated organizer event page\; date confirmed hard.\nDate quality: hard (2027-01-27)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0374\nSource: http://pvrinstitute.org/learning-hub/events/pvri-2027-bangkok
END:VEVENT
BEGIN:VEVENT
UID:v16-0375@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270218
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: 2027 Spine Summit\, annual meeting of the AANS/CNS Section on Disorders of the Spine and Peripheral Nerves\, February 18-21 2027\, Disney's Yacht & Beach Club Resort\, Orlando/Lake Buena Vista\, Florida. Source: 2027 Spine Summit Exhibitor Prospectus on dspnspinesummit.org (organizer-owned\, verified 2026-09-18). Distinct conference from ACRO 2027: The Radiation Oncology Summit (American College of Radi\nDate quality: hard (2027-02-18)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0375\nSource: https://dspnspinesummit.org/wp-content/uploads/2026/06/AAN-SpineEP27-Compressed-6-17.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-0376@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270918
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: AAO-HNSF 2027 Annual Meeting & OTO EXPO\, September 18-21 2027\, New Orleans\, Louisiana. Source: AAO-HNSF official site (entnet.org annual meeting webcasts page\, organizer-confirmed 2026-09-18).\nDate quality: hard (2027-09-18)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0376\nSource: https://www.entnet.org/education/annual-meeting-webcasts/
END:VEVENT
BEGIN:VEVENT
UID:v16-0377@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270624
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: oncology\nNote: ASCO Breakthrough (ASCO's global oncology meeting in Asia\; 2026 edition in Singapore June 25-27\, 2026)\, June 24-26 2027\, Singapore. Source: ASCO Breakthrough 'Dates to Know' page\, Future Meetings section (organizer-owned\, verified 2026-09-18).\nDate quality: hard (2027-06-24)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0377\nSource: https://www.asco.org/breakthrough/dates-know?intcmp=nw_ascoorg_brktsum_pre-cfa_site_breakthroughlandingpage_all__glob_091825_110325_qklnk__aware_text_
END:VEVENT
BEGIN:VEVENT
UID:v16-0378@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270607
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: biotech industry\nNote: BIO International Convention 2027\, June 7-10 2027\, Philadelphia\, PA (Pennsylvania Convention Center)\; world's largest biotech industry/partnering convention (~20\,000 attendees). Source: BIO official convention site (convention.bio.org) and bio.org events page save-the-date banner (organizer-owned\, verified 2026-09-18). Source URL corrected 2026-09-18 to the exact observed organizer listing page.\nDate quality: hard (2027-06-07)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0378\nSource: https://www.bio.org/events/bio-international-convention/?c1=12&page=2
END:VEVENT
BEGIN:VEVENT
UID:v16-0379@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270111
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: biotech industry\nNote: BIO Partnering @ JPM Week\, January 11-14 2027\, San Francisco\, CA\; BIO's official partnering event during the J.P. Morgan Healthcare Conference week. Source: BIO official upcoming-events listing (organizer-owned\, verified 2026-09-18). Note: this does not itself confirm the JPM conference's own dates.\nDate quality: hard (2027-01-11)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0379\nSource: https://www.bio.org/sites/default/files/2026-07/bio26_brochure_070826-digital-pages.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-0380@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270216
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: biotech industry\nNote: BIO Investment & Growth Summit\, February 16-17 2027\, Miami\, FL\; BIO investor/partnering summit. Source: BIO official upcoming-events listing (organizer-owned\, verified 2026-09-18).\nDate quality: hard (2027-02-16)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0380\nSource: https://www.bio.org/sites/default/files/2026-07/bio26_brochure_070826-digital-pages.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-0381@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271022
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: brain tumors / neuro-oncology\nNote: Joint Tumor Section Symposium\, October 22-23 2027\; Congress of Neurological Surgeons (CNS) Tumor Section specialty symposium (in-person CME\, brain tumor surgery). Source: CNS official meetings page (organizer-owned\, verified 2026-09-18).\nDate quality: hard (2027-10-22)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0381\nSource: https://www.cns.org/meetings-detail/joint-tumor-section-symposium
END:VEVENT
BEGIN:VEVENT
UID:v16-0382@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270301
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: cardiovascular / cardiometabolic / epidemiology\nNote: AHA Epidemiology & Prevention / Lifestyle and Cardiometabolic Health Scientific Sessions 2027\; March 1-4 2027 (sessions begin Mon Mar 1\, end Thu Mar 4). Location Boston\, MA per third-party reporting (not on organizer page). Source: AHA professional.heart.org organizer page (Key Dates table\, verified 2026-09-18).\nDate quality: hard (2027-03-01)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0382\nSource: https://professional.heart.org/en/meetings/epi-lifestyle?utm_source=meta&utm_medium=paid-social&utm_campaign=epi_2025&utm_content=image&utm_id=120213511874330713_v2_s03&utm_term=120214822762350713
END:VEVENT
BEGIN:VEVENT
UID:v16-0383@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270602
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: vascular surgery / peripheral vascular disease\nNote: Society for Vascular Surgery (SVS) Vascular Annual Meeting 2027 (VAM27)\, June 2-5 2027\, San Diego Convention Center\, San Diego\, CA. Scientific plenaries Jun 2-5\; exhibit dates Jun 3-4. Source: SVS official 2027 meeting page (organizer-owned\, verified 2026-09-18).\nDate quality: hard (2027-06-02)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0383\nSource: https://vascular.org/vascular-specialists/education-and-meetings/meetings/2027-vascular-annual-meeting
END:VEVENT
BEGIN:VEVENT
UID:v16-0384@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271027
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: neuromuscular / electrodiagnostic medicine\nNote: American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting 2027\, October 27-30 2027\, San Antonio\, Texas. Source: AANEM official Future Meetings page (organizer-owned\, verified 2026-09-18).\nDate quality: hard (2027-10-27)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0384\nSource: https://www.aanem.org/meetings/future-annual-meetings
END:VEVENT
BEGIN:VEVENT
UID:v16-0386@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270121
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: pediatric neuroradiology / neuroimaging\nNote: 9th ASPNR Annual Meeting\, January 21-24 2027\, Fontainebleau Miami Beach\, Miami Beach FL (pre-meeting workshops Jan 21). Source: ASPNR official meeting page (organizer-owned\, verified 2026-09-18).\nDate quality: hard (2027-01-21)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0386\nSource: https://aspnr.org/meetings/aspnr-annual-meeting/aspnr2027/
END:VEVENT
BEGIN:VEVENT
UID:v16-0387@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270126
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: hand surgery / peripheral nerve / reconstructive microsurgery\nNote: Joint 2027 annual meetings of AAHS (American Association for Hand Surgery)\, ASPN (American Society for Peripheral Nerve) and ASRM (American Society for Reconstructive Microsurgery)\, January 26-30 2027\, JW Marriott Miami Turnberry\, Aventura FL. Source: AAHS official industry prospectus (organizer-owned PDF\, verified 2026-09-18). [2026-09-27 link audit] Prior handsurgery.org file-delivery URL proved\nDate quality: hard (2027-01-26)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0387\nSource: https://meeting.handsurgery.org
END:VEVENT
BEGIN:VEVENT
UID:v16-0388@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270314
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: critical care / intensive care\nNote: 2027 Critical Care Congress\, March 14-16 2027\, San Diego Convention Center\, San Diego CA (pre-Congress educational programming March 12-13). Source: SCCM official 2027 Congress page (organizer-owned\, verified 2026-09-18).\nDate quality: hard (2027-03-14)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0388\nSource: https://www.sccm.org/annual-congress/critical-care-conference/
END:VEVENT
BEGIN:VEVENT
UID:v16-0389@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271004
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: acute myeloid leukemia (AML)\nNote: ESH 8th International Conference on Acute Myeloid Leukemia 'Molecular and Translational': Advances in Biology and Treatment\, October 4-6 2027\, Estoril Congress Centre\, Estoril\, Portugal (registration & abstract submission open). Source: ESH official conference page (organizer-owned\, verified 2026-09-18). [2026-09-27 link audit] Canonical https://esh.org/... URL re-verified live\; confirms Oct 4-6\, \nDate quality: hard (2027-10-04)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0389\nSource: https://esh.org/conference/8th-international-conference-acute-myeloid-leukemia-molecular-and-translational-advances-in-biology-and-treatment/
END:VEVENT
BEGIN:VEVENT
UID:v16-0390@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270925
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: intensive care / critical care\nNote: ESICM 40th Annual Congress (LIVES 2027)\, Copenhagen\, starting September 25 2027 ('Save the dates!'\; end date not yet published by organizer). Source: ESICM official events calendar (organizer-owned\, verified 2026-09-18).\nDate quality: hard (2027-09-25)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0390\nSource: https://www.esicm.org/accueil-v2/
END:VEVENT
BEGIN:VEVENT
UID:v16-0391@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270526
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: pediatric cochlear implantation / hearing loss\nNote: 18th European Symposium on Pediatric Cochlear Implantation\, May 26-29 2027\, Valamar Meeting & Events\, Dubrovnik\, Croatia (hosted by Croatian Society for Cochlear Implantation). Source: official ESPCI 2027 save-the-date flyer PDF (organizer-issued\, verified 2026-09-18).\nDate quality: hard (2027-05-26)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0391\nSource: https://www.espci2027.org/resources/uploads/sites/196/2026/04/ESPCI-2027-Digital-flyer.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-0392@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270605
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: nuclear medicine / molecular imaging / theranostics\nNote: SNMMI 2027 Annual Meeting\, June 5-8 2027\, Walter E. Washington Convention Center\, Washington\, DC. Source: SNMMI official annual meeting page (organizer-owned\, verified 2026-09-18).\nDate quality: hard (2027-06-05)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0392\nSource: https://snmmi.org/AM
END:VEVENT
BEGIN:VEVENT
UID:v16-0393@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270425
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: trauma and emergency surgery\nNote: 26th European Congress of Trauma and Emergency Surgery (ECTES 2027)\, April 25-27 2027\, Zurich\, Switzerland. PROVENANCE: organizer-issued save-the-date mailing from the official congress PCO (Conventus) plus corroboration from official ESTES society LinkedIn announcement and German Society for Surgery (DGCH) announcement PDF. The direct estes-congress.org registration page confirms the 2027 Zurich \nDate quality: hard (2027-04-25)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0393\nSource: https://estes-congress.org
END:VEVENT
BEGIN:VEVENT
UID:v16-0394@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271031
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Women's health / OBGYN\nNote: Montreal\, Canada (Palais des Congres de Montreal / Montreal Convention Centre)\, Oct 31-Nov 5 2027\; world's largest OBGYN meeting (~8\,000 specialists)\, gynecologic cancer and women's-health research. Official FIGO prospectus on congress.figo.org lists '31 October - 5 November | Congress onsite dates' as key dates.\nDate quality: hard (2027-10-31)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0394\nSource: https://congress.figo.org/wp-content/uploads/2026/04/FIGO-2027-Preliminary-Prospectus-V4_TB.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-0395@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270501
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Psychiatry / mental health\nNote: New York City\, NY\, May 1-5 2027\; theme 'Our Future: End Stigma\, Advance Science\, Secure Parity.' ~9\,000 psychiatrists\; CNS/psychedelic pipeline abstracts. Organizer psychiatry.org submission guidelines confirm dates and location.\nDate quality: hard (2027-05-01)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0395\nSource: https://www.psychiatry.org/psychiatrists/education/meeting-submission-and-guidelines/annual-meeting-submission-guidelines
END:VEVENT
BEGIN:VEVENT
UID:v16-0396@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270218
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Interventional cardiology\nNote: Milan\, Italy (Allianz MiCO)\, Feb 18-20 2027\; ESC family interventional cardiology congress\, expanded from Summit to Congress format. ESC registration page directly lists 'EAPCI 2027\, Milan\, 18-20 February.'\nDate quality: hard (2027-02-18)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0396\nSource: https://www.escardio.org/events/congresses/eapci-congress/registration/
END:VEVENT
BEGIN:VEVENT
UID:v16-0397@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270615
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Surgery (endoscopic/minimally invasive)\nNote: Dusseldorf\, Germany (CCD Congress Center)\, Jun 15-18 2027\; flagship EAES annual congress (1\,500-2\,000 attendees)\, minimally invasive surgery. Organizer eaes.eu events calendar directly lists '15 - 18 June 2027\, 35th international EAES congress\, Dusseldorf\, Germany.'\nDate quality: hard (2027-06-15)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0397\nSource: https://eaes.eu/events-calendar/
END:VEVENT
BEGIN:VEVENT
UID:v16-0398@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270606
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Sleep medicine / sleep and circadian science\nNote: Denver\, CO (Colorado Convention Center)\, Jun 6-9 2027\; general session Jun 6-9 (postgraduate courses Jun 5-6). Joint venture of AASM and Sleep Research Society\; ~5\,000 sleep physicians/scientists\; sleep-apnea therapy abstracts. Organizer aasm.org event page directly confirms dates and Denver location.\nDate quality: hard (2027-06-06)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0398\nSource: https://aasm.org/event/sleep-2027/
END:VEVENT
BEGIN:VEVENT
UID:v16-0399@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270907
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Pain management\nNote: Las Vegas\, NV (The Cosmopolitan)\, Sep 7-10 2027\; largest US pain management conference (~2\,300 practitioners)\; analgesic/non-opioid pipeline abstracts. Organizer conference.painweek.org directly lists 'September 7-10\, 2027 | The Cosmopolitan of Las Vegas.'\n[2026-09-23 conference re-source] URL unchanged: dedicated conference site prints the 2027 dates\; date confirmed hard.\n[2026-09-23 source revie\nDate quality: hard (2027-09-07)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0399\nSource: https://conference.painweek.org/
END:VEVENT
BEGIN:VEVENT
UID:v16-0400@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270416
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Geriatric psychiatry / CNS\nNote: San Diego\, CA (Sheraton San Diego Hotel & Marina)\, Apr 15-19 2027\; theme 'Connecting and Collaborating to Advance Geriatric Mental Health.' Conflict: AAGP organizer location page says April 15-19\; organizer prospectus PDF says April 16-20. Start 2027-04-15 used per primary location page.\nDate quality: hard (2027-04-16)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0400\nSource: https://aagponline.org/annual-meeting-location/
END:VEVENT
BEGIN:VEVENT
UID:v16-0401@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270416
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Sports medicine / musculoskeletal\nNote: Louisville\, KY\, Apr 16-21 2027\; ~2\,700 sports medicine physicians\, non-surgical musculoskeletal medicine. Organizer amssm.org conferences page directly lists '2027 AMSSM Annual Meeting\, Apr 16 - Apr 21\, 2027\, Louisville\, KY.'\nDate quality: hard (2027-04-16)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0401\nSource: https://www.amssm.org/Conferences.php
END:VEVENT
BEGIN:VEVENT
UID:v16-0402@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270421
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Pain\nNote: Glasgow\, Scotland\, Apr 21-23 2027\; European Pain Federation biennial congress (European chapter of IASP). IASP's official upcoming-events listing on iasp-pain.org gives '15th Congress of the European Pain Federation EFIC\, Glasgow\, Scotland\, 21-23 April 2027.'\nDate quality: hard (2027-04-21)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0402\nSource: https://www.iasp-pain.org/upcoming-events/list/?posts_per_page=29
END:VEVENT
BEGIN:VEVENT
UID:v16-0403@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270318
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: American Academy of Pain Medicine annual meeting\; organizer states PainConnect 2027 takes place March 18-21\, 2027 at Hyatt Regency Grand Cypress Resort\, Orlando\, FL. Distinct conference from ERS Lung Science Conference 2027 (European Respiratory Society) (separate event\, separate organizer)\; shares only the start date 2027-03-18 — not a duplicate.\nDate quality: hard (2027-03-18)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0403\nSource: https://painconnect.org/registration/
END:VEVENT
BEGIN:VEVENT
UID:v16-0404@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271015
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: American Society of Anesthesiologists annual meeting\; ASA Future Dates page lists October 15-19\, 2027\, Boston\, MA. Distinct conference from ASBMR 2027 Annual Meeting (separate event\, separate organizer)\; shares only the start date 2027-10-15 — not a duplicate.\nDate quality: hard (2027-10-15)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0404\nSource: http://asahq.org/annualmeeting/attend/futuredates
END:VEVENT
BEGIN:VEVENT
UID:v16-0405@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270513
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: ASRA Pain Medicine spring meeting\; organizer event page lists May 13-15\, 2027\, Marriott Marquis Houston\, Houston\, TX. Distinct conference from Heart Rhythm 2027 (Heart Rhythm Society Annual Meeting) (separate event\, separate organizer)\; shares only the start date 2027-05-13 — not a duplicate.\nDate quality: hard (2027-05-13)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0405\nSource: https://asra.com/events-education/annual-meetings/2027/05/13/events/52nd-annual-regional-anesthesiology-and-acute-pain-medicine-meeting
END:VEVENT
BEGIN:VEVENT
UID:v16-0406@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271118
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: ASRA Pain Medicine fall meeting\; organizer news article states it will be held November 18-20\, 2027\, in Atlanta\, GA.\nDate quality: hard (2027-11-18)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0406\nSource: https://asra.com/news-publications/asra-update-item/asra-updates/2026/08/07/dr.-ryan-s.-d-souza-receives-presidential-scholar-award
END:VEVENT
BEGIN:VEVENT
UID:v16-0407@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270927
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Neurocritical Care Society 25th Annual Meeting\; organizer future-meetings page lists September 27-30\, 2027\, Hyatt Regency New Orleans\, New Orleans\, LA.\nDate quality: hard (2027-09-27)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0407\nSource: https://www.neurocriticalcare.org/Events/Annual-Meeting/Past-Future-Annual-Meetings
END:VEVENT
BEGIN:VEVENT
UID:v16-0408@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270519
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: 28th EFORT Annual Congress\; organizer congress site states it will be held at the Megaron Athens International Conference Centre\, Athens\, Greece\, from Wednesday 19 to Friday 21 May 2027.\n[2026-09-23 conference re-source] Re-sourced from congress.efort.org homepage-path URL form to verified dedicated congress site\; date confirmed hard. (Congress is Athens\, Greece — Montpellier reference in earlier \nDate quality: hard (2027-05-19)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0408\nSource: https://congress.efort.org/
END:VEVENT
BEGIN:VEVENT
UID:v16-0409@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271007
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: European Hip Society president's welcome confirms 17th EHS Congress in London on 7-8 October 2027\; membership page adds venue Olympia\, London/Kensington.\n[2026-09-23 conference re-source] Re-sourced to dated organizer calendar page\; row clarified as European Hip Society (vs. Hernia Society) in notes\; date confirmed hard.\nDate quality: hard (2027-10-07)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0409\nSource: https://europeanhipsociety.com/hip-calendar/
END:VEVENT
BEGIN:VEVENT
UID:v16-0410@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270422
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: World Arthroplasty Congress 2027 (5th)\, April 22-23 2027\; Brussels\, Belgium. Corroborated: European Hip Society scientific calendar (co-organizing society) + Union of International Associations directory (lists organizer European Knee Society). UIA: https://uia.org/icco/search?eventcity=S%C3%A9tif&page=40 (verified 2026-09-18).\nDate quality: hard (2027-04-22)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0410\nSource: https://europeanhipsociety.com/hip-calendar/
END:VEVENT
BEGIN:VEVENT
UID:v16-0411@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270916
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: ISHA – The Hip Preservation Society\; organizer announcement states dates changed to 16-18 September 2027\, Ottawa\, Canada (19th Annual Scientific Meeting).\nDate quality: hard (2027-09-16)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0411\nSource: https://www.ishasoc.net/isha-2027-annual-scientific-meeting-host-destination-announced/
END:VEVENT
BEGIN:VEVENT
UID:v16-0412@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270916
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: 27th EURETINA Congress\; organizer future-meetings page lists 16-19 September 2027\, Bella Center\, Copenhagen\, Denmark. Distinct conference from ISHA 2027 Annual Scientific Meeting (19th\, Hip Preservation Society) (separate event\, separate organizer)\; shares only the start date 2027-09-16 — not a duplicate.\nDate quality: hard (2027-09-16)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0412\nSource: https://euretina.org/future-meetings/
END:VEVENT
BEGIN:VEVENT
UID:v16-0413@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270226
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: EURETINA Special Focus Meeting 2027 - Inherited Retinal Diseases\; organizer future-meetings page lists 26-27 February 2027\, Ljubljana\, Slovenia.\nDate quality: hard (2027-02-26)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0413\nSource: https://euretina.org/future-meetings/
END:VEVENT
BEGIN:VEVENT
UID:v16-0415@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271104
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Asian Pacific Society of Respirology 31st Congress\; organizer congress page lists 4-7 November 2027\, Bali\, Indonesia.\nDate quality: hard (2027-11-04)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0415\nSource: https://apsr.org/events/congress/
END:VEVENT
BEGIN:VEVENT
UID:v16-0416@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270204
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: critical care / intensive care medicine\nNote: Intensive Care Innovation\, February 4-5 2027\; Humanitas Congress Center\, Rozzano (Milan)\, Italy. ESICM event on the future of intensive care (AI\, precision medicine\, emerging ICU technologies). Source: ESICM official event page (organizer-owned\, verified 2026-09-18).\nDate quality: hard (2027-02-04)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0416\nSource: https://www.esicm.org/events/intensive-care-innovation2027/
END:VEVENT
BEGIN:VEVENT
UID:v16-0417@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270603
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: critical care physiology / translational intensive care\nNote: LIVES Physiology-Transbiology\, June 3-5 2027\; Athens\, Greece. ESICM specialty meeting (physiology to translational ICU research). Source: ESICM official events calendar (organizer-owned\, verified 2026-09-18).\nDate quality: hard (2027-06-03)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0417\nSource: https://www.esicm.org/congresses-events/
END:VEVENT
BEGIN:VEVENT
UID:v16-0418@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270205
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: sleep disorders / sleep medicine\nNote: Sleep Medicine Trends 2027\, February 5-7 2027\; M Resort\, Spa and Casino\, Henderson\, Nevada. AASM meeting on emerging technologies and innovations in clinical sleep medicine. Source: AASM official event page (organizer-owned\, verified 2026-09-18).\nDate quality: hard (2027-02-05)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0418\nSource: https://aasm.org/event/sleep-medicine-trends-2027/
END:VEVENT
BEGIN:VEVENT
UID:v16-0419@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270317
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: dental\, oral and craniofacial research\nNote: 56th AADOCR / 51st CADR Annual Meeting & Exhibition\, March 17-20 2027\; Minneapolis\, Minnesota. Premier dental\, oral and craniofacial research meeting. Source: AADOCR official meeting page (organizer-owned\, verified 2026-09-18). [2026-09-23 source check] Source unreachable from this network (TLS handshake timeout on both passes — not confirmed dead)\; organizer content seen live in search-index craw\nDate quality: hard (2027-03-17)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0419\nSource: http://www.aadocr.org/2027aaam
END:VEVENT
BEGIN:VEVENT
UID:v16-0420@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270915
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: retinal diseases / ophthalmology innovation\nNote: Euretina Innovation Spotlight (EIS)\, 15 September 2027\; Bella Center\, Copenhagen\, Denmark. Pre-congress innovation session adjacent to the 27th Euretina Congress (16-19 Sept 2027). Source: Euretina official future-meetings page (organizer-owned\, verified 2026-09-18).\nDate quality: hard (2027-09-15)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0420\nSource: https://euretina.org/future-meetings/
END:VEVENT
BEGIN:VEVENT
UID:v16-0421@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270224
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: obstetrics & gynecology medical education\nNote: 2027 CREOG & APGO Annual Meeting (CAAM)\, February 24-27\, 2027\, Denver\, Colorado. Joint annual meeting of the Council on Resident Education in Obstetrics and Gynecology (CREOG) and the Association of Professors of Gynecology & Obstetrics (APGO)\; theme: Fostering Inspiration - Equipping and Empowering Medical Educators in OB/GYN. Source: ACOG organizer-owned meeting page (verified 2026-09-18).\nDate quality: hard (2027-02-24)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0421\nSource: https://www.acog.org/education-and-events/meetings/creog-apgo-annual-meeting
END:VEVENT
BEGIN:VEVENT
UID:v16-0422@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270430
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: perianesthesia nursing\nNote: ASPAN 46th Annual National Conference\, April 30 - May 3\, 2027\, Sheraton New Orleans\, New Orleans\, Louisiana. Annual national conference of the American Society of PeriAnesthesia Nurses covering perianesthesia clinical care\, pediatric advancements\, emerging research\, medication and safety updates. Source: ASPAN organizer-owned 2027 National Conference page and 2027 Call for Abstracts page (verified\nDate quality: hard (2027-04-30)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0422\nSource: https://www.aspan.org/Education-Events/2027-ASPAN-National-Conference
END:VEVENT
BEGIN:VEVENT
UID:v16-0423@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270409
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: retina / ophthalmology artificial intelligence\nNote: EuretinAI 2027 (EuretinaAI: AI in Retina)\, April 9-10\, 2027\, London\, UK. Euretina dedicated meeting on artificial intelligence in retina care\, research and clinical practice. Source: Euretina organizer-owned About/EuretinaAI page (verified 2026-09-18).\nDate quality: hard (2027-04-09)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0423\nSource: https://euretina.org/euretinai-2027/
END:VEVENT
BEGIN:VEVENT
UID:v16-0424@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270220
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: cardiac electrophysiology / heart rhythm disorders\nNote: APHRS Summit 2027\, Saturday\, February 20\, 2027\, Shenzhen\, China\, held in conjunction with CardioRhythm 2027. Single-day summit of the Asia Pacific Heart Rhythm Society. Flagship APHRS 2027 Scientific Session (Taipei) dates not yet announced\; not included. Source: APHRS organizer-owned Upcoming Meetings page (verified 2026-09-18).\nDate quality: hard (2027-02-20)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0424\nSource: https://www.aphrs.org/22-meetings/meeting/495-aphrs-2027-taipei
END:VEVENT
BEGIN:VEVENT
UID:v16-0425@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270319
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: acute cardiovascular care\nNote: ESC Acute Cardiovascular Care 2027\, March 19-20\, 2027\, Seville\, Spain. Source: ESC organizer-owned congresses-events portal (explicit date ranges) corroborated by ESC 'Upcoming congresses' overview\, esCardio.org (verified 2026-09-18).\nDate quality: hard (2027-03-19)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0425\nSource: https://www.escardio.org/events/congresses/acute-cardiovascular-care/
END:VEVENT
BEGIN:VEVENT
UID:v16-0426@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270411
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: cardiac electrophysiology / arrhythmias\nNote: EHRA 2027 (European Heart Rhythm Association Congress)\, April 11-13\, 2027\, Helsinki\, Finland. Source: ESC organizer-owned congresses-events portal (explicit date ranges) corroborated by ESC 'Upcoming congresses' overview\, esCardio.org (verified 2026-09-18).\nDate quality: hard (2027-04-11)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0426\nSource: https://www.escardio.org/events/congresses/ehra-congress/
END:VEVENT
BEGIN:VEVENT
UID:v16-0427@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270415
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: preventive cardiology\nNote: ESC Preventive Cardiology 2027\, April 15-17\, 2027\, Lisbon\, Portugal. Source: ESC organizer-owned congresses-events portal (explicit date ranges) corroborated by ESC 'Upcoming congresses' overview\, esCardio.org (verified 2026-09-18).\nDate quality: hard (2027-04-15)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0427\nSource: https://www.escardio.org/events/congresses/esc-preventive-cardiology/
END:VEVENT
BEGIN:VEVENT
UID:v16-0428@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270522
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: heart failure\nNote: Heart Failure 2027 (HFA-ESC Congress)\, May 22-25\, 2027\, London\, UK. Source: ESC organizer-owned congresses-events portal (explicit date ranges) corroborated by ESC 'Upcoming congresses' overview\, esCardio.org (verified 2026-09-18).\nDate quality: hard (2027-05-22)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0428\nSource: https://www.escardio.org/events/congresses
END:VEVENT
BEGIN:VEVENT
UID:v16-0429@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270604
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: cardio-oncology\nNote: ESC Cardio-Oncology 2027\, June 4-5\, 2027\, Porto\, Portugal. Source: ESC organizer-owned congresses-events portal (explicit date ranges) corroborated by ESC 'Upcoming congresses' overview\, esCardio.org (verified 2026-09-18).\nDate quality: hard (2027-06-04)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0429\nSource: https://www.escardio.org/events/congresses
END:VEVENT
BEGIN:VEVENT
UID:v16-0430@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270611
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: cardiovascular nursing / allied professions\nNote: ACNAP 2027 (Association of Cardiovascular Nursing & Allied Professions Congress)\, June 11-12\, 2027\, Sophia Antipolis\, France. Source: ESC organizer-owned congresses-events portal (explicit date ranges) corroborated by ESC 'Upcoming congresses' overview\, esCardio.org (verified 2026-09-18).\nDate quality: hard (2027-06-11)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0430\nSource: https://www.escardio.org/events/congresses
END:VEVENT
BEGIN:VEVENT
UID:v16-0431@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270106
SUMMARY:IBRX — ANKTIVA (nogapendekin alfa inbakicept-pmln) + BCG PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: BCG-unresponsive non-muscle invasive bladder cancer with papillary disease (no CIS)\nThe FDA's decision date on ANKTIVA (nogapendekin alfa inbakicept-pmln) + BCG for BCG-unresponsive non-muscle invasive bladder cancer with papillary disease (no CIS) falls on 2027-01-06 — the agency's yes-or-no moment for ImmunityBio\, Inc.'s application.\nNote: FDA accepted the sBLA for ANKTIVA + BCG in papillary NMIBC\; PDUFA date 2027-01-06. sBLA seeks extrapolation from CIS cohort data (QUILT-3.032 Cohort A) to papillary-only disease.\nDate quality: hard (2027-01-06)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0431\nSource: https://www.businesswire.com/news/home/20260519760562/en/ImmunityBio-Announces-FDA-Acceptance-of-Supplemental-BLA-for-ANKTIVA-Plus-BCG-in-BCG-Unresponsive-Non-Muscle-Invasive-Bladder-Cancer-with-Papillary-Disease-PDUFA-Date-Set-for-January-6-2027
END:VEVENT
BEGIN:VEVENT
UID:v16-0432@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270316
SUMMARY:SkinTE (autologous cutaneous multicellular units) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Wagner Grade 1 diabetic foot ulcers\nThe FDA's decision date on SkinTE (autologous cutaneous multicellular units) for Wagner Grade 1 diabetic foot ulcers falls on 2027-03-16 — the agency's yes-or-no moment for PolarityBio\, Inc.'s application.\nNote: Private company\; no public ticker. FDA accepted SkinTE BLA for Wagner Grade 1 diabetic foot ulcers with Priority Review (Sep 15\, 2026)\; PDUFA target action date March 16\, 2027. RMAT and Breakthrough designations.\nDate quality: hard (2027-03-16)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0432\nSource: https://www.polaritybio.com/news/fda-accepts-skinte-bla-priority-review
END:VEVENT
BEGIN:VEVENT
UID:v16-0433@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270322
SUMMARY:MRK — ENFLONSIA (clesrovimab) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: RSV lower respiratory tract disease prevention\, children <2 yrs at increased risk\, second season\nNote: FDA accepted the sBLA for ENFLONSIA (clesrovimab)\; target action date 2027-03-22. sBLA supported by Phase 3 SMART trial\; would add second-season dosing for high-risk infants.\nDate quality: hard (2027-03-22)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0433\nSource: https://s2.q4cdn.com/584635680/files/doc_news/U-S--FDA-Accepts-sBLA-for-ENFLONSIA-clesrovimab-cfor-to-Update-its-Respiratory-Syncytial-Virus-RSV-Lower-Respiratory-Tract-Disease-In-S7UWZ.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-0434@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270416
SUMMARY:SEDANA — Isoflurane via Sedana Medical ACD Delivery System PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Sedation of mechanically ventilated adult ICU patients\nThe FDA's decision date on Isoflurane via Sedana Medical ACD Delivery System for Sedation of mechanically ventilated adult ICU patients falls on 2027-04-16 — the agency's yes-or-no moment for Sedana Medical AB's application.\nNote: FDA accepted the isoflurane NDA filing (announced Aug 19\, 2026)\; FDA set PDUFA target action date 2027-04-16 (company regulatory release Aug 31\, 2026). Sedana Medical announced a PDUFA target action date of 2027-04-16 for its US NDA. Listed on Nasdaq Stockholm\, not US-listed\; no US ticker. Would be first US inhaled ICU sedation therapy.\nDate quality: hard (2027-04-16)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0434\nSource: https://www.inderes.se/en/releases/sedana-medical-announces-pdufa-target-action-date-for-its-new-drug-application-in-the-us
END:VEVENT
BEGIN:VEVENT
UID:v16-0435@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270430
SUMMARY:K-911 (bimatoprost grenod / NCX 470) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Open-angle glaucoma / ocular hypertension (IOP lowering)\nThe FDA's decision date on K-911 (bimatoprost grenod / NCX 470) for Open-angle glaucoma / ocular hypertension (IOP lowering) falls on 2027-04-30 — the agency's yes-or-no moment for Kowa Pharmaceuticals America\, Inc.'s application.\nNote: FDA accepted the NDA for K-911 (bimatoprost grenod)\; PDUFA action date 2027-04-30. Parent Kowa Company (Japan) not US-listed\; no US ticker. NO-donating bimatoprost\; NDA supported by two Phase 3 trials. [Source verified 2026-09-20: The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 30\, 2027.]\nDate quality: hard (2027-04-30)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0435\nSource: https://www.kowapharma.com/newsroom/kowa-pharmaceuticals-america-fda-acceptance-k-911
END:VEVENT
BEGIN:VEVENT
UID:v16-0609@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270223
SUMMARY:ARQT — ZORYVE (roflumilast) cream 0.05% PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Mild-to-moderate atopic dermatitis in infants aged 3-24 months\nNote: FDA accepted sNDA for infant AD indication\; PDUFA date 2027-02-23 per company PR.\nDate quality: hard (2027-02-23)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-0609\nSource: https://www.arcutis.com/fda-accepts-supplemental-new-drug-application-for-arcutis-zoryve-roflumilast-cream-0-05-for-the-treatment-of-mild-to-moderate-atopic-dermatitis-in-infants-down-to-3-months/
END:VEVENT
BEGIN:VEVENT
UID:v16-1012@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270212
SUMMARY:BLTE — Tinlarebant PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Stargardt disease type 1\nThe FDA's decision date on tinlarebant for Stargardt disease type 1 falls on 2027-02-12 — the agency's yes-or-no moment for Belite Bio\, Inc.'s application.\nNote: FDA accepted NDA and granted Priority Review for tinlarebant in Stargardt disease type 1\; PDUFA date 2027-02-12 per Aug 11\, 2026 company PR. Potential first approved therapy for STGD1\; no approved therapies exist. [Source verified 2026-09-20: U.S. Food and Drug Administration accepted the New Drug Application with Priority Review for tinlarebant for the treatment of Stargardt disease type 1\; Presc\nDate quality: hard (2027-02-12)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-1012\nSource: https://www.globenewswire.com/news-release/2026/08/11/3343136/0/en/belite-bio-announces-u-s-food-and-drug-administration-acceptance-and-priority-review-of-new-drug-application-for-tinlarebant-for-the-treatment-of-stargardt-disease-type-1.html
END:VEVENT
BEGIN:VEVENT
UID:v16-1017@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270223
SUMMARY:SGIOY — Fetroja (cefiderocol) — pediatric PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: hospital-acquired / ventilator-associated bacterial pneumonia and complicated urinary tract infection (pediatric)\nNote: FDA accepted sNDA for Fetroja (cefiderocol) in pediatric patients (at least 26 weeks gestational age) with HABP/VABP and cUTI\; PDUFA date 2027-02-23 per Shionogi July 17\, 2026 PR. SGIOY is the US ADR.\nDate quality: hard (2027-02-23)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-1017\nSource: https://www.shionogi.com/content/dam/shionogi/global/news/pdf/2026/7%E6%9C%88/E_20260717_2.pdf
END:VEVENT
BEGIN:VEVENT
UID:v16-1022@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270527
SUMMARY:ZBIO — obexelimab PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: IgG4-related disease (IgG4-RD)\nThe FDA's decision date on obexelimab for IgG4-related disease (IgG4-RD) falls on 2027-05-27 — the agency's yes-or-no moment for Zenas BioPharma's application.\nNote: FDA accepted the BLA for obexelimab in IgG4-RD in Aug 2026 and assigned PDUFA target action date May 27\, 2027 (standard review\; no priority review announced). Backed by Phase 3 INDIGO (HR 0.44\, p=0.0005). Competing: Amgen Uplizna (approved Apr 2025). Added 2026-09-20 via missing-PDUFA sweep.\nDate quality: hard (2027-05-27)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-1022\nSource: https://www.globenewswire.com/news-release/2026/09/08/3357503/0/en/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event.html
END:VEVENT
BEGIN:VEVENT
UID:v16-1023@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270228
SUMMARY:BMRN — VOXZOGO (vosoritide) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: full (traditional) approval in children with achondroplasia\nNote: FDA accepted the sNDA for full (traditional) approval of VOXZOGO in children with achondroplasia\; PDUFA target action date Feb 28\, 2027 (announced 2026-07-13). Would be the first accelerated-to-full conversion in achondroplasia. Added 2026-09-20 via missing-PDUFA sweep.\nDate quality: hard (2027-02-28)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-1023\nSource: https://www.biomarin.com/news/press-releases/u-s-food-and-drug-administration-accepts-biomarins-supplemental-new-drug-application-for-full-approval-of-voxzogo-vosoritide-for-children-with-achondroplasia/
END:VEVENT
BEGIN:VEVENT
UID:v16-1031@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270917
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: NCCN's own event page: Friday Sep 17 - Saturday Sep 18\, 2027\, Sheraton Boston Hotel\, Boston\, MA. Organizer-confirmed. Distinct conference from ESMO Congress 2027 (separate event\, separate organizer)\; shares only the start date 2027-09-17 — not a duplicate.\nDate quality: hard (2027-09-17)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-1031\nSource: https://nccn.org/education-research/educational-events-and-programs/annual-congress-hematologic-malignancies
END:VEVENT
BEGIN:VEVENT
UID:v16-1032@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270414
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Official congress site (Kenes\, the organizer/PCO): MDS 2027\, 19th International Congress on Myelodysplastic Syndromes\, Leipzig\, Germany\, opening Apr 14\, 2027. Note: organizer page lists Apr 14-16 while congress flyer PDFs list Apr 14-17 - start date Apr 14 consistent\; Close date to be reconfirmed with the organizer. Distinct conference from ISHLT Annual Meeting & Scientific Sessions 2027 (47th\, In\nDate quality: hard (2027-04-14)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v16-1032\nSource: https://mds.kenes.com/
END:VEVENT
BEGIN:VEVENT
UID:v17-0004@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270131
SUMMARY:cenobamate oral suspension PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: focal seizures in adults (formulation extension for patients who have difficulty swallowing tablets)\nNote: FDA accepted the NDA for review and assigned a PDUFA target action date of January 31\, 2027 (company PR). Formulation extension of XCOPRI\; US subsidiary of SK Biopharmaceuticals. Private PDUFA gate: accepted 2027 action disclosed.\nDate quality: hard (2027-01-31)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v17-0004\nSource: https://www.prnewswire.com/news-releases/sk-life-science-inc-announces-fda-acceptance-for-review-of-new-drug-application-for-cenobamate-oral-suspension-302800433.html
END:VEVENT
BEGIN:VEVENT
UID:v17-0048@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270311
SUMMARY:BMY — Reblozyl (luspatercept) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Myelofibrosis-associated anemia (INDEPENDENCE\, with concomitant JAK inhibitor)\nNote: Phase 3 INDEPENDENCE (NCT04717414\, luspatercept vs placebo in transfusion-dependent myelofibrosis-associated anemia on concomitant JAK inhibitor) is listed on ClinicalTrials.gov. INDEPENDENCE missed its primary endpoint (p=0.0674)\; the filing relies on secondary outcomes. FDA acceptance was disclosed verbatim in the BMS Q2 2026 earnings press release (Exhibit 99.1 to 8-K\, 2026-07-30): 'The U.S. Fo\nDate quality: hard (2027-03-11)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v17-0048\nSource: https://investors.bms.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Reports-Second-Quarter-Financial-Results-for-2026/default.aspx
END:VEVENT
BEGIN:VEVENT
UID:v19-0001@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270210
SUMMARY:RYTM — setmelanotide HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Acquired hypothalamic obesity\nNote: NICE technology appraisal guidance ID6542: "Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over [ID6542] | Technology appraisal guidance | 10 February 2027". NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-02-10)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0001\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0002@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270414
SUMMARY:AZN — baxdrostat HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Uncontrolled or resistant hypertension\nNote: NICE technology appraisal guidance ID6623: "Baxdrostat for treating uncontrolled or resistant hypertension [ID6623] | Technology appraisal guidance | 14 April 2027". NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-04-14)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0002\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0003@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270113
SUMMARY:AMGN — tarlatamab HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Extended-stage small cell lung cancer\nNote: NICE technology appraisal: tarlatamab for ES-SCLC\, expected 13 Jan 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-01-13)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0003\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0004@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270317
SUMMARY:BIIB — tofersen HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: SOD1-ALS\nNote: NICE Highly Specialised Technologies appraisal: tofersen for SOD1-ALS\, expected 17 Mar 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-03-17)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0004\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0005@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270520
SUMMARY:GILD — anitocabtagene autoleucel (anito-cel) HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Relapsed/refractory multiple myeloma\nNote: NICE technology appraisal: anito-cel for R/R multiple myeloma\, expected 20 May 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-05-20)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0005\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0006@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270217
SUMMARY:REGN — linvoseltamab HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Relapsed/refractory multiple myeloma\nNote: NICE technology appraisal: linvoseltamab\, expected 17 Feb 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-02-17)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0006\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0007@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270324
SUMMARY:REGN — cemiplimab HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Adjuvant cutaneous squamous cell carcinoma\nNote: NICE technology appraisal: cemiplimab in adjuvant cSCC\, expected 24 Mar 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-03-24)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0007\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0008@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270128
SUMMARY:PFE — elranatamab HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Relapsed/refractory multiple myeloma (managed-access review)\nNote: NICE managed-access review: elranatamab\, expected 28 Jan 2027 per the NICE in-development guidance table. Managed-access review of an existing recommendation\, not a first appraisal. NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-01-28)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0008\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0009@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270506
SUMMARY:PFE — brentuximab vedotin (Adcetris) combination HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Combination therapy in lymphoma (per NICE appraisal schedule)\nNote: NICE technology appraisal: brentuximab vedotin combination\, expected 6 May 2027 per the NICE in-development guidance table. Indication per the NICE appraisal record\; confirm detail at monthly refresh. NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-05-06)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0009\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0010@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270210
SUMMARY:PFE — enfortumab vedotin + pembrolizumab HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Perioperative bladder cancer\nNote: NICE technology appraisal: enfortumab vedotin (Padcev\, Astellas/Pfizer) with pembrolizumab (Keytruda\, Merck) in perioperative bladder cancer\, expected 10 Feb 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-02-10)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0010\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0011@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270310
SUMMARY:GSK — bepirovirsen HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Chronic hepatitis B\nNote: NICE technology appraisal: bepirovirsen for HBV\, expected 10 Mar 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-03-10)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0011\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0012@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270224
SUMMARY:NVO — denecimig (Mim8) HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Haemophilia A\nNote: NICE technology appraisal: denecimig (Mim8) for haemophilia A\, expected 24 Feb 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-02-24)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0012\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0013@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270210
SUMMARY:ONC — tislelizumab HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Oesophageal cancer\nNote: NICE technology appraisal: tislelizumab for oesophageal cancer\, expected 10 Feb 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-02-10)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0013\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0014@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270513
SUMMARY:ONC — tislelizumab HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Nasopharyngeal cancer\nNote: NICE technology appraisal: tislelizumab for nasopharyngeal cancer\, expected 13 May 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-05-13)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0014\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0015@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270513
SUMMARY:RHHBY — obinutuzumab HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Lupus\nNote: NICE technology appraisal: obinutuzumab for lupus\, expected 13 May 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-05-13)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0015\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0016@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270513
SUMMARY:INCY — povorcitinib HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Hidradenitis suppurativa\nNote: NICE technology appraisal: povorcitinib for hidradenitis suppurativa\, expected 13 May 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-05-13)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0016\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0017@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270610
SUMMARY:INCY — tafasitamab + R-CHOP HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Diffuse large B-cell lymphoma\nNote: NICE technology appraisal: tafasitamab with R-CHOP for DLBCL\, expected 10 Jun 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-06-10)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0017\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0018@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270603
SUMMARY:INCY — ruxolitinib cream HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Atopic dermatitis\nNote: NICE technology appraisal: ruxolitinib cream for atopic dermatitis\, expected 3 Jun 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-06-03)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0018\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0019@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270113
SUMMARY:AZN — trastuzumab deruxtecan (Enhertu) HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Gastric cancer (guidance review)\nNote: NICE review of guidance: Enhertu (trastuzumab deruxtecan\, AstraZeneca/Daiichi Sankyo) for gastric cancer\, expected 13 Jan 2027 per the NICE in-development guidance table. Guidance review\, not a first appraisal. NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-01-13)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0019\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0020@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270411
SUMMARY:leriglitazone HTA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Highly Specialised Technologies appraisal\nNote: NICE Highly Specialised Technologies appraisal: leriglitazone\, expected 11 Apr 2027 per the NICE in-development guidance table. Sponsor is private (Minoryx Therapeutics). NICE expected publication dates slip routinely\; the date here is the agency-published expected date from the NICE in-development guidance table.\nDate quality: hard (2027-04-11)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0020\nSource: https://www.nice.org.uk/guidance/indevelopment
END:VEVENT
BEGIN:VEVENT
UID:v19-0028@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270303
SUMMARY:WiSE leadless pacing system HTA decision
STATUS:TENTATIVE
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Leadless cardiac pacing\nNote: CMS National Coverage Determination for EBR Systems' WiSE leadless pacing system (ASX:EBR). EBR's June 4\, 2026 ASX announcement quotes the CMS NCD tracking sheet: 'Final NCD expected: March 3\, 2027' (formal request accepted June 3\, 2026\; proposed decision memo due Dec 3\, 2026). CMS-projected date\, contingent on the Dec 3\, 2026 proposed memo staying on schedule — guidance\, not a confirmed final NCD\nDate quality: guidance (2027-03-03)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0028\nSource: https://www.businesswire.com/news/home/20260609744651/en/EBR-Systems-Secures-National-Coverage-Analysis-Under-TCET-Pathway-from-CMS-for-the-WiSE-System
END:VEVENT
BEGIN:VEVENT
UID:v19-0033@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270201
SUMMARY:IPAY 2029 selected-drug list Pricing decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Medicare drug price negotiation\nNote: CMS publishes the Medicare Drug Price Negotiation selected-drug list for IPAY 2029 (up to 20 Part B/D drugs\; first cycle at the 20-drug scale) — statutory deadline 2027-02-01. Per the proposed-rule summary: "for IPAY 2029\, this information would be published no later than February 1\, 2027." Statutory date\, hard. Ticker-agnostic sector event.\nDate quality: hard (2027-02-01)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0033\nSource: https://www.hfma.org/wp-content/uploads/2026/06/510136_Medicare_Drug_Price_Negotiation_Program_Proposed_Rule_Summary.pdf
END:VEVENT
BEGIN:VEVENT
UID:v19-0034@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271130
SUMMARY:IPAY 2029 maximum fair prices Pricing decision
STATUS:TENTATIVE
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Medicare drug price negotiation\nNote: CMS publishes maximum fair prices (MFPs) for IPAY 2029 selected drugs. IRA statutory deadline: November 30\, 2027 (Nov 30 of the year preceding the initial price applicability year) — publication may come earlier\; carried at guidance\, quarter bucket\, with the statutory day shown as the deadline (not a confirmed publication date). Second-round IRA negotiation wave (up to 20 Part B/D drugs selected b\nDate quality: guidance (2027-11-30)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0034\nSource: https://www.hklaw.com/en/insights/publications/2026/06/cms-issues-first-proposed-rule-for-ira-medicare-drug-price-negotiation
END:VEVENT
BEGIN:VEVENT
UID:v19-0037@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270905
SUMMARY:PFE — palbociclib (Ibrance) Patent expiry
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: US composition-of-matter patent expiry\nNote: Ibrance (palbociclib) US composition-of-matter patent RE47\,739 effective expiry September 5\, 2027 — first-wave LOE (~$4.2B annualized\, ~7% of Pfizer). Pfizer's PTE certificate extended the term to March 5\, 2027 (PR\, 2021) but noted it 'does not include potential pediatric exclusivity'\; that exclusivity has since been granted — FDA Orange Book (NDA 207103\, openFDA last_updated 2026-09-22) lists RE4\nDate quality: hard (2027-09-05)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0037\nSource: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-confirms-us-patent-term-extension-ibrancer
END:VEVENT
BEGIN:VEVENT
UID:v19-0038@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270813
SUMMARY:ALPMY — enzalutamide (Xtandi) Patent expiry
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: US patent protection expiry\nUS patent protection on enzalutamide (Xtandi) expires on 2027-08-13\, opening the door to generic competition.\nNote: Xtandi (enzalutamide) US patent protection expiry August 13\, 2027 — first-wave LOE (~$5B global\, >40% of Astellas\; Pfizer ~$1.4B/yr alliance revenue). FDA Orange Book (NDA 203415\, openFDA last_updated 2026-09-22): US 7\,709\,517 (drug substance + drug product flags\, Regents of UC) expires 20270813\; no *PED row. Astellas shareholder Q&A (17th annual meeting): 'XTANDI's substance patents will expire i\nDate quality: hard (2027-08-13)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v19-0038\nSource: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/209614Orig1s000ltr.pdf
END:VEVENT
BEGIN:VEVENT
UID:v20-0001@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270104
SUMMARY:NUVB — IBTROZI (taletrectinib) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Updated efficacy information in TKI-naive and TKI-pretreated advanced ROS1-positive non-small cell lung cancer (NSCLC)\; submission fulfills an FDA post-marketing commitment.\nThe FDA's decision date on IBTROZI (taletrectinib) for ROS1-positive non-small cell lung cancer falls on 2027-01-04 — the agency's yes-or-no moment for Nuvation Bio Inc.'s application.\nNote: FDA accepted the sNDA for IBTROZI (taletrectinib) with updated duration-of-response data in TKI-naive and TKI-pretreated advanced ROS1+ NSCLC\; target action date January 4\, 2027. Quote: "announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) with updated data for IBTROZI (taletrectinib) in both TKI-naive and TKI-pretreated advanced \nDate quality: hard (2027-01-04)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v20-0001\nSource: https://www.prnewswire.com/news-releases/nuvation-bio-announces-fda-acceptance-of-supplemental-new-drug-application-for-ibtrozi-taletrectinib-with-updated-duration-of-response-in-advanced-ros1-positive-non-small-cell-lung-cancer-302763329.html
END:VEVENT
BEGIN:VEVENT
UID:v40-0501@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270130
SUMMARY:PHAR — leniolisib (Joenja) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: activated PI3K-delta syndrome (APDS)\, lower-dose pediatric (4+ yrs\, 13 to <27 kg)\nThe FDA's decision date on lower pediatric doses of Joenja for APDS falls on 2027-01-30 — a Priority Review label expansion for Pharming Group N.V.'s rare-disease franchise.\nNote: FDA accepted sNDA and granted Priority Review for lower doses of Joenja (leniolisib)\, oral PI3K-delta inhibitor\, for children aged 4+ weighing 13 to <27 kg with APDS (activated phosphoinositide 3-kinase delta syndrome)\; PDUFA target action date January 30\, 2027 per Sep 25\, 2026 company PR. Supported by positive open-label Phase 3 data in children 4-11 yrs (reduced lymphadenopathy\, increased naive \nDate quality: hard (2027-01-30)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v40-0501\nSource: https://www.globenewswire.com/news-release/2026/09/25/3369191/0/en/pharming-announces-u-s-fda-acceptance-and-priority-review-of-snda-for-lower-doses-of-joenja-to-treat-children-with-apds.html
END:VEVENT
BEGIN:VEVENT
UID:v40-0507@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270922
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Amsterdam\, Netherlands\; September 22-25\, 2027\; dermatology/venereology\nDate quality: hard (2027-09-22)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v40-0507\nSource: https://eadv.org/events/calendar/
END:VEVENT
BEGIN:VEVENT
UID:v40-0508@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271027
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: Austria Center Vienna\, Vienna\, Austria\; October 27-30\, 2027\; sarcoma/connective tissue oncology\nDate quality: hard (2027-10-27)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v40-0508\nSource: https://www.ctos.org/Meeting/FutureMeetings.aspx
END:VEVENT
BEGIN:VEVENT
UID:v41-0002@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270204
SUMMARY:BBIO — infigratinib PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: achondroplasia (children)\nThe FDA's decision date on oral infigratinib for achondroplasia falls on 2027-02-04 — the agency's yes-or-no moment for BridgeBio's application\, and if approved it would be the first and only approved oral therapy for children with achondroplasia.\nNote: FDA accepted the NDA for oral infigratinib for filing and granted Priority Review (announced Oct 6\, 2026)\; PDUFA target action date February 4\, 2027. PROPEL 3 met its primary endpoint and key secondaries: largest AHV treatment effect of any Phase 3 study in achondroplasia (+2.10 cm/yr\, p<0.0001)\, and the first and only statistically significant improvement in both body proportionality and arm span\nDate quality: hard (2027-02-04)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v41-0002\nSource: https://www.globenewswire.com/news-release/2026/10/06/3375352/0/en/bridgebio-announces-fda-acceptance-and-priority-review-of-nda-for-oral-infigratinib-for-children-with-achondroplasia.html
END:VEVENT
BEGIN:VEVENT
UID:v41-0003@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270316
SUMMARY:AQST — Anaphylm (dibutepinephrine) sublingual film PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: type I allergic reactions\, including anaphylaxis\nThe FDA's decision date on Anaphylm (dibutepinephrine) sublingual film for type I allergic reactions\, including anaphylaxis falls on 2027-03-16 — the agency's yes-or-no moment for Aquestive Therapeutics Inc's application.\nNote: FDA accepted Aquestive's resubmission of the Anaphylm (dibutepinephrine) sublingual film NDA as complete\, classified as a Class 2 response (resubmitted September 16\, 2026\, following the January 30\, 2026 Complete Response Letter)\; PDUFA goal date March 16\, 2027.\nDate quality: hard (2027-03-16)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v41-0003\nSource: https://www.globenewswire.com/news-release/2026/10/15/3381477/0/en/aquestive-therapeutics-announces-fda-acceptance-of-anaphylm-nda-resubmission-and-pdufa-goal-date-of-march-16-2027.html
END:VEVENT
BEGIN:VEVENT
UID:v41-0004@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270614
SUMMARY:URGN — UGN-103 (mitomycin) for intravesical solution PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)\nThe FDA's decision date on UGN-103 (mitomycin) for intravesical solution for recurrent low-grade intermediate-risk NMIBC falls on 2027-06-14 — the agency's yes-or-no moment for UroGen Pharma Ltd.'s application.\nNote: FDA accepted the NDA for UGN-103 (mitomycin) for intravesical solution for recurrent low-grade intermediate-risk NMIBC (supported by the Phase 3 UTOPIA trial\, NCT06331299)\; PDUFA target action date June 14\, 2027.\nDate quality: hard (2027-06-14)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v41-0004\nSource: https://www.morningstar.com/news/globe-newswire/9847629/urogen-announces-fda-acceptance-of-the-new-drug-application-for-ugn-103-an-investigational-treatment-for-adults-with-recurrent-lg-ir-nmibc
END:VEVENT
BEGIN:VEVENT
UID:v41-0005@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270331
SUMMARY:ATRA — tabelecleucel (Tab-cel) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD)\nThe FDA's decision date on tabelecleucel (Tab-cel) for EBV+ PTLD falls on 2027-03-31 — the agency's yes-or-no moment for the Pierre Fabre/Atara application\; if approved\, Tab-cel would be the first therapy available in the U.S. for EBV+ PTLD.\nNote: FDA accepted the resubmitted BLA for tabelecleucel (Tab-cel)\, held by Pierre Fabre Pharmaceuticals\, Inc.\, as monotherapy for adult and pediatric patients two years of age and older with EBV+ PTLD who have received at least one prior therapy\; Class 2 resubmission PDUFA target action date March 31\, 2027. Atara is Pierre Fabre's U.S. partner.\nDate quality: hard (2027-03-31)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v41-0005\nSource: https://www.biospace.com/press-releases/atara-biotherapeutics-reports-that-the-resubmitted-tabelecleucel-tab-cel-biologics-license-application-has-been-accepted-by-the-u-s-food-and-drug-administration
END:VEVENT
BEGIN:VEVENT
UID:v41-0012@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20271105
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: American Heart Association Scientific Sessions\, November 5–8\, 2027\, Boston\, MA (Thomas M. Menino Convention & Exhibition Center).\nDate quality: hard (2027-11-05)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v41-0012\nSource: https://exhibitatsessions.org/scientific-sessions/future-meetings/
END:VEVENT
BEGIN:VEVENT
UID:v41-0013@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270911
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: European Respiratory Society (ERS) Congress\, September 11–14\, 2027\, Milan\, Italy. Distinct conference from the IASLC World Conference on Lung Cancer 2027\, which shares the September 11 start date (Denver).\nDate quality: hard (2027-09-11)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v41-0013\nSource: https://www.ersnet.org/congress-and-events/congress/priority-topics-congress-2027/
END:VEVENT
BEGIN:VEVENT
UID:v41-0014@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270311
SUMMARY:Conference
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Note: ACTRIMS Forum 2027\, March 11–13\, 2027\, Phoenix\, AZ. Distinct conference from the EAACI Skin Allergy Meeting 2027\, which shares the March 11 start date (Paris).\nDate quality: hard (2027-03-11)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v41-0014\nSource: https://www.forum.actrims.org/
END:VEVENT
BEGIN:VEVENT
UID:v41-0016@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270325
SUMMARY:UNCY — oxylanthanum carbonate (OLC) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis\nThe FDA's decision date on oxylanthanum carbonate (OLC) for hyperphosphatemia in patients with chronic kidney disease on dialysis falls on 2027-03-25 — the agency's yes-or-no moment for Unicycive Therapeutics\, Inc.'s application\, after two prior Complete Response Letters on manufacturing grounds.\nNote: FDA accepted Unicycive's resubmission of the OLC NDA\, deemed a Class II resubmission with a six-month review period\, and set a PDUFA target action date of March 25\, 2027. Resubmission (Sep 30\, 2026) followed a June 2026 Complete Response Letter citing manufacturing deficiencies at the original drug-product vendor\; it includes CMC data from a new vendor whose facility last received 'No Action Indic\nDate quality: hard (2027-03-25)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v41-0016\nSource: https://www.morningstar.com/news/globe-newswire/9850066/unicycive-therapeutics-announces-fda-acceptance-of-oxylanthanum-carbonate-new-drug-application-resubmission-and-pdufa-date-of-march-25-2027
END:VEVENT
BEGIN:VEVENT
UID:v41-0017@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270228
SUMMARY:PVLA — QTORIN rapamycin (3.9% rapamycin anhydrous gel) PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: microcystic lymphatic malformations\nThe FDA's decision date on QTORIN rapamycin for microcystic lymphatic malformations falls on 2027-02-28 — the agency's yes-or-no moment for Palvella Therapeutics\, Inc.'s application\, which would be the first FDA-approved therapy for this rare disease if approved.\nNote: FDA accepted Palvella's NDA for filing and granted Priority Review for QTORIN 3.9% rapamycin anhydrous gel in microcystic lymphatic malformations\; PDUFA target action date February 28\, 2027. Rolling NDA completed Aug 31\, 2026\; supported by the Phase 3 SELVA study (all six prespecified efficacy endpoints p<0.001) plus Breakthrough Therapy\, Fast Track and Orphan Drug designations. If approved\, QTORI\nDate quality: hard (2027-02-28)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v41-0017\nSource: https://www.morningstar.com/news/globe-newswire/9854829/palvella-announces-fda-acceptance-and-priority-review-of-qtorin-rapamycin-nda-february-28-2027-pdufa-target-action-date-set
END:VEVENT
BEGIN:VEVENT
UID:v41-0018@biotech-catalyst-calendar
DTSTAMP:20261101T000000Z
DTSTART;VALUE=DATE:20270201
SUMMARY:AGIO — mitapivat PDUFA decision
STATUS:CONFIRMED
TRANSP:TRANSPARENT
DESCRIPTION:Indication: sickle cell disease (patients aged 16 years and older)\nThe FDA's decision date on mitapivat for sickle cell disease falls on 2027-02-01 — the agency's yes-or-no moment for Agios Pharmaceuticals\, Inc.'s supplemental application\, extended three months while FDA weighs whether a REMS is necessary.\nNote: FDA extended the PDUFA goal date for the mitapivat sickle cell disease sNDA from November 1\, 2026 to February 1\, 2027\, after classifying Agios's response to an FDA information request as a major amendment (three-month extension). The sNDA was submitted under the accelerated approval pathway and granted Priority Review. FDA's Oct 9\, 2026 request concerned whether a Risk Evaluation and Mitigation St\nDate quality: hard (2027-02-01)\nDetails: https://risdiplam.github.io/biotech-catalyst-calendar/#/event/v41-0018\nSource: https://www.morningstar.com/news/globe-newswire/9856739/agios-announces-new-pdufa-goal-date-of-february-1-2027-for-mitapivat-sickle-cell-disease-snda-company-is-launch-ready-and-in-labeling-discussions-with-fda
END:VEVENT
END:VCALENDAR